



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number: **0 634 490 A1**

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: **94202002.5**

(22) Date of filing: **11.07.94**

(69) Declaration under Rule 28(4) EPC (expert solution)

(51) Int. Cl.⁶: **C12N 15/56, C12N 9/24,
C12N 1/21, C12N 15/57,
C12N 15/75, //(C12N1/21,
C12R1:10,1:125,1:19),
(C12N9/24,C12R1:07)**

(30) Priority: **15.07.93 GB 9314780**

(43) Date of publication of application:
18.01.95 Bulletin 95/03

(64) Designated Contracting States:
AT BE CH DE DK ES FR GB IT LI NL PT SE

(71) Applicant: **SOLVAY (Société Anonyme)**
Rue du Prince Albert, 33
B-1050 Bruxelles (BE)

(72) Inventor: **De Buyt, Eric**
Vieux Chemin 5
B-1630 Linkebeek (BE)
Inventor: **Lahaya, Andrée**
avenue des Pagodes 304
B-1020 Bruxelles (BE)
Inventor: **Ledoux, Pierre**
avenue des Dix Arpents 100

B-1200 Bruxelles (BE)
Inventor: **Amory, Antoine**
avenue Bal Air 44
B-1330 Rixensart (BE)
Inventor: **Detroz, René,**
chaussée de Louvain 534,
B-1390 Ohain (BE)
Inventor: **Andre, Christophe,**
ruelle des Croix 39,
B-1390 Grez-Dolceau, (BE)
Inventor: **Vetter, Roman,**
Warneckeweg 1,
D-31303 Burgdorf, (DE)

(74) Representative: **Meyers, Lillane et al**
Solvay & Cie S.A.
Département de la propriété industrielle
310, rue de Ransbeek
B-1120 Bruxelles (BE)

(54) **Xylanase derived from a bacillus species, expression vectors for such xylanase and other proteins, host organisms therefor and use thereof.**

(57) A purified xylanase derived from B. Pumilus PRL B12 is disclosed. This xylanase is efficient for use in the biobleaching of wood pulp, permitting a strong reduction in the quantity of chlorine used and AOX compounds produced in classical and ECF wood pulp bleaching sequences as well as the quantity of ozone used in TCF sequences. The gene coding for the xylanase was isolated and purified and used to construct an expression vector therefor. A recombinant host strain of B. licheniformis is also disclosed which is efficient for expressing heterologous enzymes, including the xylanase when transformed by the expression vector.

EP 0 634 490 A1

The present invention relates to heterologous enzymes produced by recombinant strains of Bacillus licheniformis and, in particular, to a xylanase derived from Bacillus pumilus PRL B12 which is efficient for use in the biobleaching of lignocellulosic pulp, expression vectors and recombinant Bacillus licheniformis hosts for the expression of the xylanase, and the use of the xylanase in the biobleaching of lignocellulosic pulp.

A common objective in the manufacture of products (such as paper products) from lignocellulosic pulps is to provide a pulp from which the product produced has as high a final brightness as is possible. A major factor that limits such final brightness is the quantity of lignin present in the pulp.

Lignin in such lignocellulosic pulps is mostly bound up with hemicellulose in a lignocellulosic complex. A major interface between the lignin and the remainder of the carbohydrates of the lignocellulosic complex is formed by xylan (1,4- β -D-xylan) which is bonded thereto. To remove the lignin from the pulp, these bonds must first be broken.

Conventionally, lignocellulosic pulps, such as wood pulp, are delignified by being chemically-cooked. While being extremely useful for its purposes, (up to ninety-five per cent of the lignin present may be removed therefrom by such chemical-cooking), chemical-cooking cannot, by itself, reach higher levels of delignification without severely attacking the carbohydrates in the pulp. Thus, cooking must be stopped before the loss of carbohydrates becomes too important and before further delignification has occurred. This remaining lignin imparts a brown color to the cellulosic fibers in the pulp, thereby preventing the product fabricated therefrom from having as high a final brightness as possible.

To obtain further delignification of the pulp after chemical-cooking, various "bleaching" sequences are used. Conventionally, such bleaching sequences include "Classical" (or conventional) bleaching sequences and Elemental Chlorine Free bleaching sequences. These bleaching sequences include a delignification stage followed by a series of bleaching stages. In the delignification stage, the pulp is first subjected to a chlorine and/or chlorine dioxide treatment step, usually followed by an alkaline extraction step.

While being effective for facilitating the removal ("delignification") of substantial quantities of lignin from the chemically-cooked pulp, treatment of the pulp nonetheless suffers from drawbacks. Perhaps the most troublesome of these drawbacks (especially in the case of classical sequences) is that their use results in discharges of chlorinated compounds which have been linked to the formation of absorbable organic halides (AOX). AOX compounds have been associated with environmental toxicity. It is believed that the AOX concentration in effluents is directly linked to the quantity of chlorine and chlorine dioxide compounds that are used in the process. Thus, AOX levels have become commonly used as a standard in the industry for determining the content of chlorinated organics in the bleaching plant's effluents. As such, industries, such as the wood pulp and paper industry, which make products from such pulp have come under increasing pressure and regulation to reduce both AOX production and the consumption of both chlorine and chlorine dioxide used during bleaching.

To reduce or eliminate AOX production and the consumption of Cl_2 and ClO_2 while still achieving acceptable levels of delignification, it has been proposed to utilize various hemicellulolytic enzymes to facilitate lignocellulosic pulp delignification (in a process commonly referred to as "biobleaching"). In particular, it has been proposed to use of a wide variety of diverse xylanases which are secreted by a range of various fungi and bacteria, including bacteria of the genus Bacillus, for treating the pulp. However, these attempts have had varying degrees of success depending upon the precise characteristics of the xylanase which has been employed therefor. To be successfully employed in commercial biobleaching applications, a xylanase should be efficient over the pH range naturally possessed by the pulp when the xylanase is utilized during biobleaching. Furthermore, the xylanase should be devoid of any residual cellulase activity.

In biobleaching, xylanase may be added to the pulp after it has exited the chemical-cooker, but before it has been chemically-treated. At that point, the pulp typically has a pH in the range of about 7.0 to 9.5. The identification and utilization of a xylanase which is efficient over this alkaline pH range would greatly reduce the control that must be maintained over that aspect of the process conditions as well as reduce the quantity of chlorine and reactive oxidants needed to chemically-treat the chemically-cooked pulp.

It has been known for some years that microorganisms of the species Bacillus pumilus extracellularly secrete xylanases. Indeed, as early as 1960 it was disclosed that the culture media of B. pumilus contains xylanases which make this culture broth useful for food processing applications (see Canadian Letters Patent No. 603,953 and United States Letters Patent No. 2,821,501). However, nowhere do those patents either disclose, teach or suggest the isolation and/or purification of the enzymes (including the xylanases) from the culture broth into which they are secreted. Furthermore, it was reported therein that in pH's above 8, those xylanases will generally be inactivated.

To the best of our knowledge, the xylanase of only two strains of Bacillus pumilus have ever been isolated and/or purified : Bacillus pumilus IPO and Bacillus pumilus DSM 6124. However, there is nothing to

indicate whether the xylanase from B. pumilus PRL B12 would have potential usefulness in biobleaching applications.

Only one xylanase from any strain of B. pumilus has ever been proposed for use in biobleaching, and that xylanase was from a specially designed mutant -- B. pumilus DSM 6124. The isolation and purification of the xylanase secreted from B. pumilus DSM 6124, as well as its use in biobleaching has been disclosed in International Publication No. WO 91/02839 and International Publication No. WO 92/03540. However, as reported therein, the xylanase of strain DSM 6124 has an optimum pH of only 5-7 and appears to be of limited efficiency for the delignification of pulps having pH's of up to only about 8.5.

The presence, in the culture broth, of extracellular xylanases secreted by Bacillus pumilus PRL B12 and B. pumilus PRL B92 has also long been known, being reported as early as 1954 (1). It was further reported therein that, when in the milieu of the culture broth, the xylanase of B. pumilus PRL B12 is stable up to pH 11. However, nowhere does that reference either disclose, teach or suggest the isolation and/or purification of the xylanase from the culture broth into which it is secreted, nor is there any indication whatsoever in (1) as to what physical characteristics such an isolated and/or purified xylanase would have when not in the milieu of the culture broth. Furthermore, those xylanases have never been proposed for use in the biobleaching of chemical pulp.

It is known that, when in the culture broth into which they are secreted, xylanases are often contaminated by other enzymes. This can make the isolation and purification of the xylanase difficult and costly. This is particularly significant in that there is no information in (1) as to whether or not those xylanases ever were, or ever could be, isolated and/or purified, nor is there any information in (1) as to how difficult or successful one could expect such a task to be.

Furthermore, it is known that, in the culture broth, the contamination of the xylanase by other enzymes can effect the apparent physical characteristics of the xylanase, including its efficiency over different pH ranges. This aspect is particularly notable in light of the fact that xylanases exhibit a wide variety of characteristics, even when secreted from extensively homologous microorganisms of the same genus.

Thus, it can be seen that there still remains a need to locate and provide an isolated and/or purified xylanase which is efficient for the delignification of lignocellulosic pulp having a pH in the alkaline range of 7-9.5, so as to be useful for the pretreatment of lignocellulosic pulp by facilitating delignification of the lignocellulosic pulp before the bleaching thereof. In this fashion, the xylanase of the present invention permits a reduction in the quantity of chlorine, chlorine dioxide and other/or reactive oxidants which are needed to be utilized in the bleaching sequences for chemically-treating the lignocellulosic pulp, as well as a reduction in the production of AOX compounds, while still providing a lignocellulosic pulp that has an acceptably-low lignin content (as measured by the Kappa Index of the pulp).

It is further desirable to provide a host for expressing various enzymes, such as the xylanase, in good yields. In this regard, it is noted that if the enzyme yield from the host organism is too low, then enzyme production will be inefficient and too expensive.

While strains of B. pumilus are often cited as being hyper-producers of xylanase, the yields obtained therefrom are nonetheless too low to permit their use in industrial applications.

In order to obtain an increase in the yield of B. pumilus xylanase, it has been proposed to clone the xylanase gene(s) from Bacillus pumilus IPO into compatible hosts for achieving the heterologous expression of the xylanase in increased yields from the transformed hosts. The expression of the xylan-degrading genes of Bacillus pumilus IPO in species of Escherichia coli, Bacillus subtilis and Saccharomyces cerevisiae have all been disclosed. However, we are not aware of any disclosure of the usefulness of those transformed hosts for industrial applications.

In spite of the above references, it nonetheless still remains desirable to identify and prepare suitable hosts which are stable, capable of use in commercial applications and which are capable of extracellularly secreting xylanase, and in particular xylanase derived from B. pumilus PRL B12, in suitable yields.

Strains of Bacillus licheniformis are routinely used as hosts for the heterologous extracellular expression of various neutral and acidic enzymes (mainly proteases and alpha-amylases) in large scale industrial situations.

While success has been achieved in obtaining the heterologous expression of these neutral and acidic enzymes noted above, the use of the strains of B. licheniformis for the heterologous production of enzymes, such as xylanase, under alkaline conditions nonetheless presents several drawbacks. One of these drawbacks is that B. licheniformis is a producer of alkaline proteases, which can degrade xylanases and other enzymes under alkaline conditions. Such a feature is an obvious disadvantage and disincentive to the use of B. licheniformis as a host for the secretion of a xylanase. Further, even if making the deletions of the alkaline protease gene had been suggested, there would be no guarantee of success, especially in light of International Publication No. WO 91/02792, wherein it was reported that the presence of even a part of a

protease gene can induce a reduction in the productivity of heterologous enzymes by the strain. Accordingly, to the best of our knowledge, no one has suggested the use of strains of Bacillus licheniformis for the heterologous expression of xylanase.

Thus, it can be seen that there further remains a need to provide a stable host capable of expressing
5 such a xylanase in high yields.

It is a primary object of the present invention to identify, purify and provide a xylanase which is efficient for facilitating the delignification of lignocellulosic pulp, and in particular wood pulp, having a broad alkaline pH range and, in particular, a preferred pH range of 7.0-9.5.

It is another primary object of the present invention to identify and prepare suitable hosts which are
10 stable, easy to use in commercial applications and which are capable of extracellularly secreting, in suitable yields, various enzymes, and in particular xylanase, especially xylanase derived from B. pumilus PRL B12, under alkaline conditions.

It is a further object of the present invention to isolate and purify the gene (nucleotide sequence) that codes for the xylanase of the present invention, as well as to provide an appropriate vector therefor which is
15 useful when transformed in a suitable host, such that heterologous expression of the xylanase of the present invention may be achieved.

A still further object of the present invention is to provide expression vectors which include the nucleotide that codes for the xylanase of Bacillus pumilus PRL B12 and methods for the preparation thereof.

In still another aspect of the present invention, a further object is to provide expression hosts for the
20 expression vectors of the xylanase of the present invention, as well as for other enzymes, such as alpha-amylase, pullulanase, subtilisin and alkaline protease.

In still yet another aspect of the present invention, a further object is to provide an enzymatic treatment employing such a xylanase which permits a reduction in the quantity of chlorine, chlorine dioxide and other
25 reactive oxidants used for delignification during biobleaching, as well as a reduction in the production of AOX compounds while still permitting a pulp to be obtained that has an acceptably-low lignin content.

In accordance with the teachings of the present invention, a purified xylanase that is derived from B. pumilus PRL B12 and mutants and variants thereof, is disclosed. This xylanase consists essentially of the amino acid sequence of amino acids numbered 1 to 200 of figures 1a and 1b and mutants and variants of
30 this amino acid sequence. This xylanase is efficient for facilitating the delignification of pulp having a pH, preferably, in the range of 7.0 to 9.5.

Alternatively, a purified xylanase is disclosed having a molecular weight of about 26 kDa as determined by an SDS-PAGE gel electrophoresis method as defined herein, an isoelectric point of about 9.8-9.9 in terms of a value as measured by an isoelectric focusing method as defined herein, an optimum temperature of
35 about 55 °C as measured by a xylan hydrolysis assay method as defined herein and an optimum pH of about 6.5-7.5 as measured by a xylan hydrolysis assay method, as defined herein.

In another alternative, a purified xylanase is disclosed that has a molecular weight of about 26 kDa as determined by an SDS-PAGE gel electrophoresis method as defined herein and a molecular weight of about 22,500 kilodaltons (and more precisely about 22,534 kilodaltons) as deduced from the amino acid
40 sequence of the mature xylanase by a deduction method as defined herein.

Finally, it is noted that the purified xylanase disclosed herein has, for the biobleaching of lignocellulosic pulp, an optimum xylanolytic activity of about 7.5-8.5 as measured by the kappa index of the lignocellulosic pulp treated thereby in a method defined herein.

By the term "as defined herein" what is meant is the method defined in in the various examples set
45 forth below.

By the term "derived from" when used in reference to B. pumilus PRL B12 and the xylanase and the nucleotide sequences disclosed herein, what is meant are the xylanase and the nucleotide sequences which are native to (or which are identical to those xylanase and nucleotide sequences which are native to) B. pumilus PRL B12.

In further accordance with the teachings of the present invention, a xylanase is disclosed herein that is heterologously-produced by and obtained from a microorganism of the genus Bacillus of the type which has a naturally-occurring alkaline protease gene. It is preferred that such hosts be aerobic. It is further preferred that such hosts not be thermophilic. Examples of such hosts include microorganisms of the species Bacillus subtilis and Bacillus licheniformis. Other examples include microorganisms of the species Bacillus alkalophilus, Bacillus lentus and Bacillus amyloliquefaciens. It is further preferred that this xylanase be
55 heterologously-produced by and obtained from such a microorganism which has had the alkaline protease gene deleted therefrom, such as B. licheniformis SE2 delap1, B. licheniformis SE2 delap3, B. licheniformis SE2 delap6 and B. subtilis SE3. It is still further preferred that the xylanase be expressed heterologously

by, and obtained from, strains of such microorganisms which have been transformed to include the xylanase coding sequence (and preferably, the entire xylanase gene) of B. pumilus PRL B12, so that the xylanase can be expressed thereby.

Alternatively, disclosed herein is a xylanase obtained from a strain of Bacillus pumilus, such as B. pumilus PRL B12.

In still further accordance with the teachings of the present invention, a process is disclosed herein for producing a xylanase in a Bacillus species. The process includes transforming a suitable strain of a Bacillus with a nucleotide sequence coding for at least the mature portion of the xylanase (SEQ ID NO:34). In this manner, a Bacillus having a complete xylanase gene expression unit is formed. The Bacillus is then cultured under suitable conditions for the expression of xylanase. Finally, the process disclosed involves recovering the xylanase from the culture. In a preferred embodiment, the Bacillus is Bacillus licheniformis. It is further preferred that the nucleotide sequence is derived from Bacillus pumilus PRL B12.

In yet further accordance with the teachings of the present invention, the gene (DNA molecule) coding for the xylanase of B. pumilus PRL B12 has been isolated therefrom and purified. In this regard, the nucleotide sequence of the entire xylanase gene of B. pumilus PRL B12 is disclosed. This nucleotide sequence includes those nucleotides coding for the mature xylanase, as well as those nucleotides coding for the precursor xylanase (SEQ ID NO:31) of B. pumilus PRL B12 (SEQ ID NO:32). This nucleotide sequence further includes promoters of the gene, as well as upstream and downstream nucleotide sequences.

In still further accordance with the teachings of the present invention, suitable expression vectors are disclosed herein. A preferred expression vector having, as a component thereof, the nucleotide sequence coding for the mature xylanase is disclosed, in addition to methods for the preparation thereof. Alternatively, this expression vector can further include the nucleotide sequences (SEQ ID NO: 30) coding for the precursor xylanase. If desired, the upstream and/or downstream coding sequences of the xylanase gene may also be included. Most preferably, this expression vector includes the entire xylanase gene (SEQ ID NO:35) seen in figures 1a and 1b. This most preferred expression vector is pUB-BPX12.

Other expression vectors disclosed herein include pUBDEBRA1, pKAC1, pLI1, pL7SBT, pL7TAKA, each of which code for various other proteins, so as to permit the heterologous expression thereof by the expression hosts disclosed herein.

In still further accordance with the teachings of the present invention, suitable hosts have been identified and methods for the preparation thereof have been disclosed. The hosts are stable, are able to operate effectively under varying process conditions and are capable of the heterologous production of enzymes, including xylanase derived from B. pumilus PRL B12, in good yields. Preferably, these hosts include (biologically pure cultures of) strains of Bacillus licheniformis and, in particular, the strain designated herein as B. licheniformis SE2 delap1 and mutants and variants thereof, such as the strains designated herein as B. licheniformis SE2 delap3 and mutants and variants thereof and B. licheniformis SE2 delap6 and mutants and variants thereof. Disclosed herein are also methods for preparing such strains of B. licheniformis by performing chromosomal deletions of the gene(s) thereof which code for alkaline protease. In this regard, deletion plasmids LD1, LD3 and LD6, and the methods for the construction thereof, are also disclosed herein.

In yet further accordance with the teachings of the present invention, the use of the xylanase of the present invention is disclosed herein as a treatment in the biobleaching of lignocellulosic pulp, such as Kraft wood pulp. Preferably, the xylanase may be used as a pretreatment in conjunction with traditional bleaching sequences. More particularly, use of the xylanase is disclosed as a pretreatment to classical bleaching sequences of the type CEDPD and C/DEDPD, as those sequences are defined herein. Also more particularly, use of the xylanase is disclosed as a pretreatment in conjunction with Elemental Chlorine Free Sequences of the type DEDPD, as those sequences are defined herein.

In still yet further accordance with the teachings of the present invention, the use of the xylanase of the present invention is disclosed herein in the biobleaching of lignocellulosic pulp in Totally Chlorine Free sequences. More particularly, use of the xylanase in Totally Chlorine Free sequences of the type OQPZP. It is especially preferred that, in such sequences, the xylanase be used in conjunction with the sequestrant (Q)step to give the sequence OX/QPZP.

It is especially preferred to use this xylanase in the sequences described above for the biobleaching of wood pulp and, more particularly, kraft wood pulp.

In still yet further accordance with the teachings of the present invention, an enzymatic treatment employing the xylanase is disclosed. Preferably, such a treatment is a pretreatment for classical and Elemental Chlorine Free bleaching sequences or in conjunction with one of the steps of a Totally Chlorine Free bleaching sequence. This enzymatic treatment permits a reduction in the quantity of chlorine, chlorine

dioxide and/or other reactive oxidants needed to be used for subsequently chemically-treating the lignocellulosic pulp, as well as a reduction in the production of AOX compounds, while still permitting a pulp to be obtained which has an acceptably-low lignin content. Furthermore, this enzymatic pretreatment either : (a) does not diminish the final product brightness achieved (in the case of classic sequences or ECF sequences); or (b) still provides a final product brightness which is satisfactory while employing acceptable quantities of reactants (in the case of TCF sequences).

The use of the xylanase of the present invention in the treatment (biobleaching) of lignocellulosic pulp is usually done in a separate stage. It may also be done in combination with sequestrants. The xylanase can therefore be used not only to reduce the chemical charges of chlorine, chlorine dioxide and/or other reactive oxidants, such as oxygen, ozone or peroxide, but it also decreases the costs of the biobleaching process.

It is noted that the xylanase of the present invention has use not only in the biobleaching of lignocellulosic pulp (as will be discussed at greater length below), but it is also useful in the preparation of xylooligosaccharides from vegetable materials.

Figures 1a and 1b show the nucleotide sequence of the gene coding for the xylanase of the present invention and the amino acid sequence of the precursor xylanase of the present invention, including the presequence and the mature enzyme, coded for by the nucleotide sequence.

Figure 2 is a graph illustrating the results of the SDS-PAGE Analysis for determining the molecular weight of the xylanase of the present invention in which the Y-axis represents the molecular weight in kilodaltons (kD) and the X-axis represents the migration distance in millimeters (mm).

Figure 3 is a graph illustrating the results of the PAGE analysis for determining the isoelectric point (pI) of the xylanase of the present invention in which the Y-axis represents the pI, the X-axis represents distance from cathode in millimeters (mm) and Xyl represents the pI obtained for the xylanase of the present invention.

Figure 4 is a restriction map of the plasmid pUB-BPX12.

Figure 5 is a restriction map of plasmid pUBDEBRA1.

Figure 6 is a restriction map of plasmid pKAC1.

Figure 7 is a restriction map of plasmid pLI1.

Figure 8 is a restriction map of plasmid pL7SBT.

Figure 9 is a restriction map of plasmid pL7TAKA.

Figure 10 illustrate the *in vivo* chromosomal deletions made in Bacillus licheniformis SE2 by the deletion plasmids pLD1, pLD3 and pLD6.

Figure 11 is a restriction map of plasmid pLD1.

Figure 12 is a restriction map of plasmid pLD3.

Figure 13 is a restriction map of plasmid pLD6.

The xylanase of the present invention is produced by gene(s) derived from Bacillus pumilus PRL B12. The invention also concerns mutants and variants of this xylanase.

As used herein, the term "mutants and variants of this xylanase" and like phrases, refer to xylanases that are obtained by the alteration of the DNA nucleotide sequence of the structural gene coding for the xylanase of the present invention or a derivative thereof. Such variants or mutants of the xylanase of the present invention may be expressed and produced when the DNA nucleotide coding sequence encoding therefor is inserted into a suitable vector and/or a suitable host organism. This definition includes such xylanases which are either heterologously expressed by the host organisms or homologously expressed by their natural host cells.

The xylanase of the present invention is a 1,4- β -D-xylan xylanhydrolase, designated as EC 3.2.1.8 (endoxylanase). This xylanase is synthesized as a larger "precursor protein" (SEQ ID NO:1) consisting of a "presequence" (SEQ ID NO:25) and a "mature" protein sequence (SEQ ID NO: 24). The amino acid sequence of the xylanase of the present invention, including the presequence thereof can be seen by reference to figures 1a and 1b.

As used herein, the terms "precursor protein", "precursor enzyme" or "precursor xylanase", what is referred to is the entire protein, enzyme or xylanase, including all "pre" (and/or "pro") sequences, as transcribed and translated and before any post-translational modifications thereof.

As used herein the terms "mature protein", "mature enzyme" and/or "mature xylanase", what is referred to is that portion of the protein, enzyme or xylanase which, after post-translational modifications thereto, is secreted into and found in the culture broth.

As used herein, the term "presequence" what is referred to is that portion of the protein, enzyme or xylanase which is not secreted extracellularly, being removed (by enzymatic cleaving or otherwise) from the "mature" sequence before the extracellular excretion of the "mature" portion.

The isolated and purified xylanase of the present invention has been extensively characterized herein, as will be discussed at length below, as being an enzyme having a "mature sequence" of 200 amino acids. As determined from its amino acid sequence (which has been deduced from the nucleotide sequence of the structural gene coding therefor), the xylanase has a molecular weight of 22,534.55 kilodaltons (kDa) (as compared to a molecular weight of 26 kDa, as determined by SDS-PAGE analysis) and a pI of 9.56 (as compared to a pI of 9.8-9.9, as determined by isoelectric focusing). The xylanase of the present invention exhibits an effective xylanolytic activity over a broad temperature range of from below 40 °C to above 65 °C, with an optimum temperature of 55 °C. The optimum pH determined for this xylanase under assay conditions is 6.5-7.0, a range which one would expect to be too low to be efficient for use in biobleaching.

However, as will be discussed at length below surprisingly, despite the low optimum pH exhibited by the xylanase of the present invention under assay conditions, it is nonetheless efficient for facilitating the delignification of pulps having an alkaline pH over the entire pH range of 7.0 to 9.5.

This xylanase is devoid of any residual cellulase activity.

The xylanase of the present invention may be homologously expressed and extracellularly secreted into the culture broth by *Bacillus pumilus* PRL B12. This xylanase may also be heterologously-expressed and extracellularly-excreted into the culture broth by other *Bacillus* hosts, such as strains of *B. licheniformis*, *B. subtilis*, *B. alkalophilus*, *B. lentus* and *B. amyloliquefaciens* which have been transformed with the appropriate xylanase gene(s) from *B. pumilus* PRL B12 using rDNA techniques. Regardless of which approach is taken, the xylanases from these two different hosts have identical or partially identical immunochemical properties as can be determined immunologically by various well-known cross-reaction identity tests. (See Axelsen, N.H., Handbook of Immunoprecipitation-in-Gel Techniques, Blackwell Scientific Publications (1983), chapters 5 and 14).

The xylanase of the present invention is producible by the cultivation of *Bacillus pumilus* PRL B12 and mutants and variants thereof.

As used herein, the term "mutants and variants", when referring to *B. pumilus* PRL B12 refers to cells obtained by the alteration of the DNA nucleotide sequence of the structural gene coding for the xylanase thereof.

Xylanase-producing *B. pumilus* PRL B12 can be cultivated under aerobic conditions in nutrient medium containing assimilable carbon and nitrogen together with other essential nutrient(s). The medium can be composed in accordance with principles well-known in the art. Furthermore, it is noted that *B. pumilus* PRL B12 is not thermophilic.

During cultivation, the host cells secrete xylanase extracellularly. This permits the isolation and purification (recovery) of the xylanases to be achieved by, for example, separation of cell mass from a culture broth (e.g. by filtration or centrifugation) while avoiding lysis. The resulting cell-free culture broth can be used as such or, if desired, may first be concentrated (e.g. by evaporation or ultrafiltration). If desired, the xylanase can then be separated from the cell-free broth and purified to the desired degree by conventional methods, e.g. by column chromatography, or even crystallized.

Preferably, the xylanase of the present invention is isolated and purified from the xylanase-culture broth into which it is extracellularly secreted by : (1) concentration of the supernatant of the host culture; (2) passing the concentrated supernatant over an ion-exchange column; and (3) passing the concentrated supernatant over a hydrophobic interaction column.

The xylanase is also obtainable with the use of recombinant DNA technology methods well-known to those skilled in the art, such as by isolating a DNA fragment encoding the xylanase; combining the DNA fragment with an appropriate expression signal in an appropriate plasmid vector; introducing the plasmid vector in an appropriate host (either as an autonomously replicating plasmid or integrated into the chromosome); cultivating the host organism under conditions leading to expression of the xylanase; and recovering the xylanase from the culture broth.

The xylanases also may be produced essentially as described in Japanese Patent Specification No. 86039036 and/or in International Publication No. WO 92/03540.

The xylanase of the present invention may be used to supplement various lignocellulosic pulp bleaching sequences. Such bleaching sequences are employed after chemical-cooking of the pulp to obtain further delignification and bleaching in order to obtain the final brightness desired. Such bleaching sequences commonly have a first delignification stage, wherein a chemical-treatment step is performed followed by an alkaline extraction step. This delignification stage is then followed by a series of bleaching stages.

Classical (or conventional) bleaching sequences use elemental chlorine (Cl₂) alone or in addition to chlorine dioxide (ClO₂) to chemically-treat (by chlorination) the cooked pulp (followed by alkaline extraction) in the delignification stage. Elemental Chlorine Free (ECF) bleaching sequences use ClO₂ in place of Cl₂ in the delignification stage.

While exhibiting reduced AOX levels, such ECF sequences nonetheless still result in some AOX production. Further, ClO_2 is more expensive than Cl_2 . Finally, chlorine dioxide is not as efficient in chemically-treating the cooked pulp as chlorine. Thus, higher quantities of ClO_2 are needed (in comparison to Cl_2) to achieve the same results. Use of such higher ClO_2 concentrations increases the production of AOX compounds that are associated therewith, as well as increasing the costs of the overall process. Indeed, in industrial applications the amount of ClO_2 needed for such bleaching can mandate a substantial investment in equipment, such as an "on-site" ClO_2 generator.

In Totally Chlorine Free (TCF) bleaching sequences, other sources of reactive oxidants, such as peroxides (i.e., hydrogen peroxide) and ozone, are used for chemically-treating the pulp in the delignification stage in place of elemental chlorine and chlorine dioxide. While achieving desired reductions in AOX levels, such TCF sequences may not achieve as high a level of delignification as desired. Furthermore, such reactive oxidants can cause degradation of the pulp. Finally, the reactive oxidants used in such TCF sequences can be quite expensive, further increasing the costs associated with such biobleaching sequences.

As will be discussed at length below, we have found that when used in conjunction with ECF and Classical sequences, pretreatment of pulp with the xylanase of the present invention surprisingly permits substantial reductions in the levels of the chlorine and/or chlorine dioxide charge needed during the subsequent delignification stage. A direct consequence of this is a reduction of the AOX concentration in the plant's effluents, resulting in a benefit to the environment. We have further found that a xylanase pretreatment aids ECF and classical sequences, as well as TCF sequences to achieve as high a final brightness as possible (as, for example, measured by the *ISO of the pulp).

The invention is particularly directed at pulps which have undergone a chemical-cooking. After cooking, xylan (after losing its side chains) precipitates back into the fiber structure of the pulp, where it protects the lignin that remains in the fibers. We believe that the xylanase of the present invention removes a part of that reprecipitated xylan, exposing the lignin and facilitating its subsequent removal during the delignification stage of the bleaching sequence. All types of lignocellulosic materials, such as wood, used for the production of chemical pulps are suitable for use with the process of the present invention. These pulps include, in particular, those used for kraft pulps, namely, the coniferous (soft) woods such as, for example, the various species of pines and firs and the deciduous (hard) woods, such as for example beech, oak, eucalyptus and hornbeam, as well as other sources of lignocellulosic materials, such as flax and jute.

As used herein, "Kappa Index" refers to a measurement of the amount of lignin present in wood pulp. The Kappa Index is a number representing the volume (in milliliters) of 0.1 N potassium permanganate (KMnO_4) solution consumed by one gram of moisture-free pulp under the conditions specified in, and following the procedures described in, TAPPI (Technical Committee of the Association of the Pulp and Paper Industry) Standard # T236cm-85 (1985).

As used herein, "*ISO" refers to a measurement of the brightness of the paper produced from the pulp. This value is a factor of the reflectability of the paper made from the pulp under the conditions specified in, and following the procedures described in, ISO (the International Organization for Standardization) Standard # 2469, as published in reference # ISO 2470-1977(F), as supplemented by Standard # 2470.

As used herein, the term "Multiple", "Chlorine multiple" and/or "Active Chlorine Multiple" represents the oxidizing power of the chlorine and chlorine dioxide, expressed as chlorine equivalents and calculated as :

$$[\text{Cl}_2 + \text{ClO}_2 (2.63) \% \text{ on oven-dried pulp (o.d.p.)}] / \text{kappa number of the unbleached pulp.}$$

As used herein, the term "XU" refers to Xylanase Units, a figure arrived at as described below in Example 2.

The xylanase can be added at various points throughout the various bleaching processes. Preferably, xylanase is added to the pulp after the chemical-cooking thereof, but before the chemical-treatment step of the delignification stage of the bleaching sequence occurs. In this respect, the xylanase provides a kind of pretreatment which permits a reduction in the quantities of chlorine, chlorine dioxide and/or other reactive oxidants which need to be used in the chemical-treatment step of the delignification stage of, the bleaching sequence. Xylanase can be added in either its purified form, or it may be in a concentrated or unconcentrated culture broth.

Classical pulp bleaching sequences employ elemental chlorine (Cl_2) optionally with chlorine dioxide (ClO_2) for the delignification stage thereof. Common examples of classical bleaching sequences are : CEDPD (Chlorine chemical-treatment, alkaline Extraction, Dioxide, Peroxidase and Dioxide) and C/DEDPD (Chlorine/Dioxide chemical-treatment, alkaline Extraction, Dioxide, Peroxide and Dioxide). In each of these

classical sequences, delignification substantially occurs in the first two steps, which are referred to herein as the "delignification stage" of the bleaching sequence. Bleaching is what substantially occurs in the remaining steps, which are referred to herein as the "bleaching stage" of the bleaching sequence.

Use of the Xylanase (X) of the present invention in classical bleaching sequences is, preferably, as a pretreatment of the pulp in a separate step immediately preceding the chemical-treatment step of the delignification stage. It may be done without a washing therebetween. Used in this fashion, the B. pumilus PRL B12 xylanase permits substantial reductions, in the range of approximately 15 % (for softwoods) to 40 % (for hardwoods), in the quantity of chlorine that is needed to be utilized in the delignification stage. This reduction in chlorine is achieved while still maintaining a pulp having an acceptable level of delignification (as measured by the kappa index of the pulp having a particular pH at the time of the xylanase treatment).

ECF pulp bleaching sequences employ chlorine dioxide for the delignification and for the bleaching of pulp. A common example of an ECF sequence is : DPDPD (Dioxide chemical-treatment, Peroxide, Dioxide, Peroxide and Dioxide). In these ECF sequences, delignification substantially occurs in the first two steps, which are referred to herein as the "delignification stage" of the bleaching sequence. Bleaching is what substantially occurs in the remaining steps, which are referred to herein as the "bleaching stage" of the bleaching sequence.

Use of the Xylanase (X) of the present invention in such ECF bleaching sequences is, preferably, as a pretreatment of the pulp as a separate step immediately preceding the chemical-treatment step of the delignification stage and without a washing therebetween. Used in this fashion, the B. pumilus PRL B12 xylanase permits a substantial reductions in the quantity of chlorine dioxide that is needed to be utilized in the delignification stage. This reduction is achieved while actually improving the delignification achieved in the delignification stage.

TCF pulp bleaching sequences employ a reactive oxidant, in the absence of Cl₂ and/or ClO₂, for delignification and bleaching phases thereof. A common example of a TCF sequence is : OQPZP (Oxygen, sequestrant, Peroxide, oZone and Peroxide). In such sequences, the goal is to reduce, as much as possible, the quantity of ozone (or other reactive oxidant) in the fourth step while obtaining as high a final brightness of the wood pulp as possible (as measured by the final *ISO of the pulp). This reduction of ozone is important in that ozone can degrade the pulp.

Use of the Xylanase (X) of the present invention in such TCF bleaching sequences is, preferably, performed in conjunction with the sequestrant step (such that the sequence is OX/QPZP). Used in this fashion, the B. pumilus PRL B12 xylanase permits reductions in the quantity of ozone that is needed to be utilized in the sequence. This reduction was achieved while improving the final brightness achieved (as measured by the final *ISO of the pulp).

In another aspect of the present invention, the gene coding for the xylanase of the present invention has been isolated and purified, as described herein. The nucleotide sequence coding for the xylanase may be isolated from the chromosomal DNA of Bacillus pumilus PRL B12 by conventional cloning methods. The xylanase coding sequence may be obtained on a partial Sau3AI DNA fragment of 1022 base pairs (bp). The nucleotide sequence of this fragment has been determined, as is seen with reference to figures 1a and 1b (SEQ. ID NO: 1), wherein "N" represents an unidentified nucleotide. This 1022 bp fragment includes the nucleotide sequence coding (SEQ ID NO: 26) for the mature xylanase and/or the nucleotide sequence (SEQ ID NO: 27) coding for the xylanase presequence (SEQ ID NO:33) and/or the upstream coding sequences (SEQ ID NO: 28) and/or the downstream nucleotide sequences (SEQ ID NO: 29) of the xylanase gene of the present invention.

In still another aspect, the present invention includes expression vectors which contain nucleotide sequence(s) (structural gene) that code for a particular protein or protein(s), such as xylanases, α -amylases, pullulanases and alkaline proteases, and which expression vectors may be used for the transformation of suitable host cells in order to obtain the expression of the protein(s) coded for thereby.

As used herein, the term "Expression Vector" refers to any discrete DNA sequence which includes a replicon as well as other regions of DNA (nucleotide sequences), so as to independently function in host as a complete gene expression unit.

By the term "complete gene expression unit" what is meant is a structural gene and the promoter region(s) and regulatory region(s) required for transcription and translation.

By the term "promoter region" what is meant is any region upstream of a structural gene's coding sequence which permits binding of RNA polymerase and transcription and/or translation of the coding sequence to occur.

By the term "regulatory region" what is meant is any region which regulates transcription and/or translation of the structural gene.

By the term "structural gene" what is meant is a coding sequence which serves to be the template for the synthesis of RNA and which allows the synthesis of the protein of interest in a host therefor.

Depending upon the specifics of the case, the nucleotide sequence(s) of the expression vectors can include the nucleotide sequence(s) which code(s) for either precursor protein(s) or mature protein(s).

5 In addition to the sequence(s) discussed above, the expression vectors of the present invention may include further nucleotide sequences which aid in the maintenance of the expression vector and/or which aid in the expression and/or secretion of the protein(s) to be produced by the protein coding sequence(s). Such additional sequences may be either independent from the protein coding sequence(s), or they may be operably linked thereto.

10 By the term "independent from the protein coding sequence(s)" what is meant is that the synthesis, expression and/or secretion of the protein(s) coded for by the protein coding sequence(s) of the expression vector neither regulates, promotes nor otherwise controls or effects the said additional nucleotide sequence(s).

By the term "operably linked to the protein coding sequence(s)" what is meant is that the synthesis, 15 expression and/or secretion of the protein(s) coded for by the protein coding sequence of the expression vector regulates, promotes and/or otherwise controls or effects the said additional nucleotide sequence(s) which are so associated (operably linked) therewith.

The expression vectors of the present invention may be constructed from nucleotide sequence(s) that are either homologous or heterologous to the host cells which they transform (or are intended to transform).

20 By the term "homologous to the host cells", what is meant is that the nucleotides sequence(s) of the expression vector are either derived from the host strain, or a strain belonging to the same species, (which they are intended to transform) or are modified or synthetically created, such that they function equivalently to nucleotides of the host strain (the expression host).

By the term "heterologous to the host cells", what is meant is that the nucleotide sequence(s) of the 25 expression vector are derived from a strain which is different from the host strain (which they are intended to transform) nor modified or synthetically created, such that they function equivalently to nucleotides of the host strain (the expression host).

The expression vectors of the present invention may be constructed from nucleotide sequence(s) that are either homologous or heterologous to one another.

30 By the term "nucleotide sequence(s) that are homologous" what is meant are nucleotides sequence(s) (of the expression vectors) that are either derived from the same source organism and/or are modified or synthetically created, such that they function equivalently to nucleotides of the same source organism.

By the term "nucleotide sequence(s) that are heterologous" what is meant are nucleotide sequences(s) (of the expression vectors) that are derived from different source organisms and/or are modified or 35 synthetically created, such that they do not function equivalently to nucleotides of the same source organism.

By the term "isolated" what is meant is that the nucleotides referred to (such as those of the expression vector) are not present in their naturally-occurring environment.

40 The nucleotide sequence(s) of the expression vectors of the present invention are prepared by restriction of DNA to prepare DNA fragments and by ligation of such DNA fragments to prepare recombinant molecules.

By the term "DNA fragment(s)", what is meant is one or more DNA nucleotides which are bonded to one another after having been subjected to restriction with a restriction enzyme. The nucleotides of such fragments may be either heterologous or homologous to one another.

45 By the term "recombinant molecule(s)", what is meant are at least two DNA nucleotides which are bonded to one another after having been subjected to ligation by a ligase (for example T4 DNA ligase). The nucleotides of such recombinant molecules may be either heterologous or homologous to one another.

Unless otherwise noted herein, such restriction of DNA to prepare DNA fragments used in the invention, ligation of such fragments to prepare recombinant molecules used in this invention, as well as introduction 50 of DNA into host microorganisms or cells are carried out using known techniques disclosed in the various references cited herein. Also, unless otherwise stated, conditions are selected to avoid denaturation of the DNA and enzymes employed. For example, generally, the pH is buffered to remain in a range of neutrality and the temperature is generally kept below about 60 °C. Preferably, restriction is generally carried out at about 37 °C, except for some enzymes with are issued from thermophilic bacteria.

55 Restriction enzymes and ligases used in carrying out this invention are commercially available and should be used in accordance with the manufacturers instructions included therewith.

The various fragments and final constructions may be joined together in accordance with conventional techniques. In many cases, genes have been isolated and restriction mapped, as well as sequenced. To

that extent, one is able to select the sequence of interest, such as the coding sequence for the protein of interest, by restriction of the gene. Further to that extent, one may employ further manipulation, as is necessary (such as by in vitro mutagenesis using synthetic oligonucleotides) in order to modify the DNA sequence and/or to provide a fragment of a particular size, including the desired sequence, and having the appropriate termini. Linkers and adapters can be used for joining sequences, as well as for replacing lost or deleted sequences, where the restriction site is internal to the region of interest. The various fragments which are isolated, may be purified by electrophoresis, electroeluted, ligated to other DNA fragments, cloned, reisolated and further manipulated, as desired.

The expression vectors of the present invention may be autonomously replicating vectors. That is to say, when transformed into a host organism, these vectors will be independently maintained (either as no copy, single copy or multicopy plasmids) without significant recombination or integration with the host's chromosomal DNA. Alternatively, these vectors may be of the type where the expression system becomes integrated chromosomally into the host.

Suitable expression vectors used in the practice of the present invention will, in general, be those which are compatible with the organism with which the vector will be transformed. In this regard, they will, for example, have compatible regulatory sequences and origins of replication. They will further, preferably, be multicopy and have selectable marker gene(s) (for example, gene(s) coding for antibiotic resistance). Examples of such suitable expression vectors include phages, plasmids, cosmids, transposons and chromosomal integration vectors. In addition, the expression vector of this invention may be used to integrate the expression elements and heterologous gene elements into the host chromosome following conventional techniques, such as are described in Saunders, et al., J. Bacteriol., 157, 718-726 (1984).

A preferred expression vector of the present invention include the nucleotide sequence (SEQ ID NO: 26) that codes for the mature xylanase of B. pumilus PRL B12. These expression vectors may further include the nucleotide sequence coding for the presequence (SEQ ID NO: 27) of the xylanase of B. pumilus PRL B12. These expression vectors may still further include various xylanase promoter and regulatory regions (sequences) (SEQ ID NO: 28 and SEQ ID NO: 29) of B. pumilus PRL B12 which influence/control the expression of the said xylanase. Expression vector pUB-BPX12 is such an expression vector.

It is noted here that, alternatively, other regulatory sequences (homologous or heterologous) can be used to control the expression of the xylanase gene.

Expression vector pUB-BPX12 includes the following elements : (a) a fragment of vector pUB131 which carries the replication functions for Bacillus; and (b) the xylanase coding sequence from B. pumilus PRL B12. In this regard, it is noted that, as shall be discussed at length below in the Examples, the xylanase gene from B. pumilus PRL B12 was isolated by cloning in plasmid pUB131.

The vector pUB131 is an autonomously replicating multicopy plasmid which was constructed from (is a derivative of) the well-known plasmid pUB110. Plasmid pUB110 is well-characterized with its full DNA sequence known and its genes defined in McKenzie et al., Plasmid, 15:93-103 (1986).

pUB131 is constructed by, first, deleting a DNA sequence from pUB110, which encodes a polypeptide believed to be involved in mobilization functions. This deleted sequence is then replaced by a synthetic polylinker sequence, generating plasmid pUB131. The construction and sequence of vector (plasmid) pUB131 is reported in detail in (2).

The xylanase coding sequence, present on the 1022 bp partial Sau3AI fragment was subcloned into vector pUB131, thus generating expression vector pUB-BPX12. Most preferably, pUB-BPX12 contains the following elements :

1. a sequence from pUB131 responsible for autonomous replication of the plasmid in the host. (This feature permits pUB-BPX12 to be used in a number of Bacillus host species, such as strains of B. subtilis, B. pumilus, and B. licheniformis, B. alkalophilus, B. lentus and B. amyloliquefaciens, etc.);
2. a gene from pUB131 that confers resistance to kanamycin or neomycin to the host cells;
3. a gene from pUB131 that confers resistance to phleomycin to the host cells; and
4. the gene from encoding the xylanase from B. pumilus PRL B12. A restriction map of plasmid pUB-BPX12 can be seen in figure 4.

Other expression vectors provided herein include the nucleotide sequence that codes for the pululanase of Bacillus deramificans T 89.117D (pUBDEBRA1), or the nucleotide sequence that codes for the α -amylase of B. licheniformis ATCC 9789 (pL7TAKA), or the nucleotide sequence that codes for the alkaline protease of B. licheniformis SE2 (pLI1), or the subtilisin (alkaline protease) of Bacillus subtilis 168 (pKAC1 and pL7SBT). The expression hosts of the present invention are strains of the genus Bacillus which are compatible with the expression vector for the protein desired to be expressed thereby. Preferably, these strains are aerobic. It is further preferred that these strains not be thermophilic. Such strains include B. subtilis, B. pumilus, and B. licheniformis, B. alkalophilus, B. lentus and B. amyloliquefaciens. Preferably, the

alkaline protease gene(s) thereof has (have) been deleted from these expression hosts.

The preferred host(s) of the present invention for the expression of the xylanase of the present invention are (biologically pure cultures of) recombinant strains derived from Bacillus licheniformis. As a species that is routinely used in the large-scale industrial production of extracellular enzymes, mainly proteases and alpha-amylases, it is an interesting host for the expression of cloned gene products on an industrial scale.

The particular recombinant strain of B. licheniformis used herein for host(s) for the expression vectors of the present invention is B. licheniformis SE2. B. licheniformis SE2 is asporogenic under production conditions. B. licheniformis SE2 is deficient in neutral protease production and is an alkaline protease producer.

The alkaline protease produced by B. licheniformis SE2 is first synthesized intracellularly as an inactive precursor called "pre-pro-enzyme". The "pre" and the "pro" sequences are eliminated during the translocation of the polypeptide into the extracellular culture medium, thus generating the secreted active alkaline protease.

In order to obtain the deleted SE2 strains (delap1, delap3 and delap6) therefrom, the DNA coding sequence of the gene coding for at least the mature part of the alkaline protease was removed (as shall be discussed at length below) from the bacterial chromosome, thereby creating a deleted strain which is unable to produce a functional alkaline protease.

As used herein, the term "mature part of the alkaline protease" refers to the active alkaline protease, that is to say, the secreted alkaline protease polypeptide that is found in the culture broth.

In these host(s), B. licheniformis SE2 has been treated using rDNA techniques in order to obtain the (biologically pure cultures of) deleted strains of the present invention : B. licheniformis SE2 delap1, SE2 delap3 and SE2 delap6, all of which do not produce alkaline proteases that may deleteriously degrade the heterologous protein expressed thereby before such heterologous protein can be recovered. Furthermore, the particular B. licheniformis SE2 delap recombinant strain may be transformed with pUB-BPX12, described above, which carries the xylanase coding sequence from B. pumilus PRL B12, as well as the genes coding resistance to kanamycin and neomycin.

The construction of the particular B. licheniformis SE2 delap strain involved the following steps :

1) The gene coding for the alkaline protease was isolated from the chromosomal DNA of B. licheniformis SE2 together with its flanking 5' and 3' regions, and then introduced into pUB131, a replicating plasmid in B. subtilis;

2) Deletion plasmids were constructed having the nucleotide sequence that codes for the mature part of the alkaline protease deleted therefrom;

3) B. licheniformis SE2 was then transformed with the resulting deletion plasmid;

4) The chromosomal protease gene from the B. licheniformis SE2 strain was then replaced by the deleted sequence of the plasmid through homologous recombination, generating a particular deleted B. licheniformis SE2 strain; and

5) The plasmid used for the deletion was eliminated from the deleted SE2 strains by curing.

The resulting deleted B. licheniformis SE2 delap strains thus differ from the parent SE2 strain only in that chromosomal deletions of the alkaline protease DNA sequence, including the DNA sequence coding for the mature protease has occurred. A schematic representation of the deletion is given in figure 10.

While described above with reference to B. licheniformis SE2, it is to be understood that the same strategy may be employed to prepare deleted strains of the other Bacillus strains (B. subtilis, B. alkalophilus, B. lentus and B. amyloliquefaciens) as is needed and desired.

MATERIALS AND METHODS

Materials

Unless otherwise specified in the following Examples (and in various of the preceding Examples), the following materials were utilized therein :

Luria-Bertani ("L-B", sometimes referred to herein as L-B media) media is either, in a liquid form or in its solid form containing 15 g/l agar. The liquid L-B medium is that which is described in (3) at page A.1. The solid L-B medium is that which is described in (3) at page A.4.

The protease detection plates were made of L-B medium supplemented with 1 % (w/v) Skim milk.

The composition and preparation of Tris-acetate (TAE) buffers and Tris-borate (TBE) buffers used herein are those which are described in (3) at 6.7.

The composition and preparation of the of TE buffers used herein are those which are described in (3) at page B.20.

AZCL-pullulan and AZCL-xylan were purchased from Megazyme Pty. Ltd.

The polyacrylamide sequencing gels were made according to the procedure described by (3) at pages 13.45-13.53, using 6 % (w/v) acrylamide, instead of a gradient.

Acrylamide was purchased from Biozym.

5 DM3 medium was made according to the procedures described in (4) at pages 150-151.

Bacterial strains and plasmids were obtained from the sources, using the catalogue numbers as are set forth below in Table 1 :

TABLE 1

10

15

20

25

30

35

Bacterial Strains and Plasmids Sources		
Strain or Plasmid	Origin	Catalog No.
E. coli MC1061	Clontech Laboratories ¹	C-1070-1
E. coli JM109	Clontech Laboratories ¹	C1005-1
B. subtilis 168	B.G.S.C. ²	1A1
B. subtilis BR151	B.G.S.C. ²	1A40
B. subtilis PSL1	B.G.S.C. ²	1A510
B. subtilis 512 PN-	B.G.S.C. ²	1A274
B. deramificans T 89.117D	B.C.C.M. (L.M.G.) ³	P-13056
B. licheniformis	A.T.C.C. ⁴	9789
Bacillus pumilus PRL B12	A.T.C.C. ⁴	6631
pUB110	B.G.S.C. ²	1E6
pBR322	Clontech Laboratories ¹	6210-1
pBS-	Stratagene ⁵	211202
pUC18	Clontech Laboratories ¹	6110-1
pACYC184	Biolabs ⁶	#401-M
pMK4	B.G.S.C. ²	1E29

¹ Clontech Laboratories, (U.S.A.).

² B.G.S.C. is the collection of the BACILLUS GENETIC STOCK CENTER (Ohio State University) U.S.A.

³ B.C.C.M. (L.M.G.) is the Belgian Coordinated Collections of Microorganisms (Laboratorium voor Microbiologie), University of Gent, Belgium.

⁴ A.T.C.C. is the American Type Culture Collection, (U.S.A.).

⁵ Stratagene, Inc. (U.S.A.).

⁶ Biolabs New England. (U.S.A.).

40 Plasmids pUB131, pUBC131 and pUBC132 were constructed as described in European Patent Application No. 90116322.0.

Bacillus licheniformis SE2 was deposited under the provisions of the Budapest Treaty on 21 June 1993, in the Belgian Coordinated Collections of Microorganisms, Laboratorium voor Microbiologie, K.L. Ledeganckstraat 35, B-9000 Gent, Belgium, under Accession Number LMG P-14034.

45 Bacillus subtilis SE3 was deposited under the provisions of the Budapest Treaty on 21 June 1993, in the Belgian Coordinated Collections of Microorganisms, Laboratorium voor Microbiologie, K.L. Ledeganckstraat 35, B-9000 Gent, Belgium, under Accession Number LMG P-14035.

50 Bacillus pumilus PRL B12, (originally deposited in the American Type Culture Collection (ATCC) in May 1938 under Accession Number 6631) was deposited under the provisions of the Budapest Treaty on 24 June 1993 in the American Type Culture Collection (ATCC) 12301 Parklawn Drive, Rockville, Maryland 20852, U.S.A., under Accession Number 55443.

Methods and Techniques

55 Unless otherwise specified in the following Examples, the following methods and techniques were utilized therein :

When the term "cloned", "subcloned" and/or "introduced" is used when speaking of DNA fragments, what is meant is, when necessary, the digestion (restriction) or donor and/or receptor DNA sequences, the treatment of cohesive protruding 3' and 5' ends thereof (when needed and/or desired), the separation of

such fragments according to size and/or extraction of such fragments (when needed and/or desired), the dephosphorylation of such fragments, including linearized vectors (as needed and/or desired) and the ligation of such fragments to one another to form a recombinant DNA molecule. Such a definition further includes the transformation of host cells with such recombinant molecules, the selection of such transformants and the isolation and purification of recombinant DNA molecules (such as plasmids) from such host cells.

Digestions and restrictions of (donor and receptor) plasmids, chromosomal DNA and the like were performed using one or several restriction enzymes, as necessary, to isolate the DNA fragment of interest. The restriction enzymes used for such digestions are commercially available from a number of manufacturers. The restriction digestions were performed under the conditions specified in, and following the procedures described by (3) at 5.28 - 5.32, except that the restriction reaction was scaled up by a factor of 10, so as to obtain a sufficient amount of DNA for further purification steps.

Cohesive protruding 5' ends of fragments were made blunt by treatment with Klenow fragment of *E. coli* DNA polymerase I under the conditions specified in, and following the procedures described by (3) at F.2-F.3.

Cohesive protruding 3' ends of the fragment were made blunt by treatment with Bacteriophage T4 DNA polymerase, under the conditions specified in, and following the procedures described by (3) at F.4 - F.5.

Separations of the DNA fragments according to size (after the restrictions were terminated) were performed by Agarose Gel Electrophoresis using 0.8 % (w/v) agarose in a tris-acetate buffer, under the conditions specified in, and following the procedures described by (3) at 6.01 - 6.19. For separation of small fragments (<1000 bp), the agarose concentration used was increased to between 1 and 1.2 % (w/v).

Other agarose gel electrophoresis were done under the conditions specified in, and following the procedures described in (3) at 6.9-6.15, using tris-acetate buffer (TAE) for preparative gels (DNA purification), or tris-borate (TBE) buffer for analytical purposes.

Following separation according to size, the DNA fragments of interest were extracted from the agarose gel and, unless otherwise indicated therein, isolated and purified following either the filtration method using centrifugation, as described in Zhu, et al., Bio/Technology 3, 1014-1016 (1985), or the purification method using glass beads, provided under the tradename "Gene Clean" by Bio101.

Dephosphorylations of the DNA fragments of interest, including linearized vectors, were performed under the conditions specified in, and following the procedures described by (3) at 1.60-1.61.

Ligations of DNA fragments, to the linearized vectors or otherwise, were performed as under the conditions specified in, and following the procedures described in (3) at 1.68-1.69. This method was used regardless if the fragments to be ligated contained cohesive or blunt ended termini. In this regard, it is noted that the ligase utilized herein was T4 DNA ligase.

Synthetic oligonucleotides were constructed following the procedure described in Beaucage, S.L., et al., (1981), Tetrahedron Letters 22:1859-1882 and using β -cyanoethyl phosphoramidites in a Bioscience Cyclone Synthesizer.

Labelling of synthetic oligonucleotides was performed by phosphorylation with [γ -³²P]ATP using Bacteriophage T4 polynucleotide kinase under the conditions specified in, and following the procedures described by (3) at page 11.31-11.33.

Clonings, subclonings, and/or introductions of double-stranded DNA linkers (used as donor DNA) into receptor vectors were achieved by assembling two complementary synthetic oligonucleotides, which were obtained in a phosphorylated form. Both oligonucleotides were mixed in 1 x KGB buffer, described by (3) at 5.31, and heated at 95 °C for 10 minutes. The mixture was then permitted to slowly (over a minimum time of 15 minutes) cool down to room temperature. In this fashion, the double-stranded synthetic linkers were provided. These double-stranded synthetic linkers were then utilized as the donor DNA fragment either directly in ligations, as discussed above, or submitted to restriction digestion, as discussed above, before such ligation, as is desired and specified in the Examples.

DNA constructions were carried out by utilizing strains of *E. coli* as a cloning host. Alternatively, and when specified therein, strains of *Bacillus subtilis* were used as the cloning host.

Transformations of *E. coli* host cells were performed using the CaCl₂ method under the conditions specified in, and following procedures described by (3) at 1.82-1.84.

Alternative (and specified) transformations of *E. coli* host cells were performed using electroporation under the conditions specified in, and following the procedures described by (3) at 1.75-1.81.

The *E. coli* host cells used in the transformations were *E. coli* MC1061.

Transformations of *B. subtilis* host cells were performed using the Competent Cell Method under the conditions specified in, and following the procedures described by (5) at 9-11.

Alternative (and specified) transformations of *B. subtilis* host cells were performed using the Protoplast technique under the conditions specified in, and following the procedures described by (6) at 150-151, with the following modifications : lysozyme powder was added at 5 mg/ml in SMMP, instead of 1 mg/ml as is specified in step 7 of the procedure described in (6) at page 151 (the incubation time needed to obtain a maximal lysis with lysozyme was 60 minutes); and the regeneration was done on DM3 medium supplemented with 200 µg/ml of Kanamycin.

The *B. subtilis* host cells used in the transformations were *B. subtilis* BR151.

Transformations of *Bacillus licheniformis* host cells were performed using the Protoplast technique under the conditions specified in, and following the procedures described by (6) at 150-151, with the following modification : lysozyme powder was added at 5 mg/ml in SMMP, instead of 1 mg/ml as is specified in step 7 of the procedure described in (6) at page 151. The incubation time needed to obtain a maximal lysis with lysozyme was 60 minutes.

Selection of *E. coli* transformants was carried out with the use of an appropriate antibiotic. For all plasmids derived from pBR322, pUC18, pUBC131, or pMK4, Ampicillin (100 µg/ml of culture medium) was used. For all plasmids derived from pACYC184, Tetracycline (12.5 µg/ml of culture medium) was used.

Selection of *B. subtilis* transformants was carried out on Luria and Bertani medium supplemented with the appropriate antibiotic. Kanamycin (25 µg/ml) was used for all plasmids derived from pUB110, pUB131 and pUBC131. Chloramphenicol (10 µg/ml) was used for all plasmids derived from pMK4.

Selection of *B. licheniformis* transformants was carried out with Phleomycin at 14 µg/ml (for pUB110 and pUB131 derivatives), and the regeneration time on DM3 plates [see (6) at page 150] was 3-4 days. The colonies appearing on the DM3 plates were transferred onto L-B plates containing the appropriate antibiotic for further work.

The isolation of plasmids from selected transformant colonies was performed by the colonies being grown in small scale cultures and then subjected to the alkaline lysis method, under the conditions specified in, and following the procedures described by (3) at 1.25 -1.28. However, for transformant colonies of *B. subtilis* host cells, that procedure was modified in the following two aspects : (a) the glucose in the lysis buffer solution I described in (3) at 1.25 was replaced by 20 % (w/v) sucrose, and lysozyme (10 mg/ml) was freshly added; and (b) the lysis was carried out for 30 minutes at 37 °C, before the addition of solution II.

Restriction analyses carried out on the small scale plasmid DNA preparations were performed under the conditions specified in, and following the procedures described by (3) at 1.85 and by (6) at 374-379. The relevant restriction enzymes used for the analysis are shown in the restriction maps given in the corresponding figures for each new plasmid construction.

In some cloning experiments, two orientations of the donor DNA fragment were expected, respective to the receptor plasmid. In such cases, in order to select the proper orientation of the fragments, a screening was carried out on the small scale plasmid DNA preparations by restriction analysis, under the conditions specified in, and following the procedures described by (3) at 1.25-1.28. The relevant restriction sites utilized in the screening are shown in the restriction maps given in the corresponding figures for each plasmid construction.

After having selected the desired plasmid(s) large scale preparations were carried out using the alkaline lysis method under the conditions specified in, and following the procedures described by (3) at 1.38-1.39, followed by a CsCl purification performed under the conditions specified in, and following the procedures described by (3) at 1.42-1.45.

Plasmids from *E. coli* were prepared and purified using the alkaline lysis method under the conditions specified in, and following the procedures described by (3) at 1.38-1.39, followed by a CsCl purification performed under the conditions specified in, and following the procedures described by (3) at 1.42-1.45.

Plasmids from *B. subtilis* and/or *B. licheniformis* were isolated, prepared and purified using the alkaline lysis method under the conditions specified in, and following the procedures described by (3) at 1.38-1.39, and modified in the two following points : (a) the glucose in the lysis buffer solution I described in (3) at 1.38 was replaced by 20 % sucrose, and lysozyme was freshly added at 10 mg/ml; and, (b) the lysis was carried out during 30 minutes at 37 °C, before the addition of solution II. The plasmid was then purified by a CsCl purification under the conditions specified in, and following the procedures described by (3) at 1.42-1.45.

DNA extractions were from bacterial species which had been grown in L-B medium for 16 hours at 37 °C.

Extractions and purifications of chromosomal DNA from cell cultures were obtained by centrifugation of the cultures while in the stationary phase, at 5000 rpm for 10 minutes. The resulting pellet was then suspended in 9 ml of 0.1M TRIS-HCl buffer (pH 8.0), 0.1M EDTA and 0.15M NaCl containing 18 mg of lysozyme. The resulting solution was then incubated for 15 minutes at 37 °C. Following this incubation, the

lysate was treated with 200 µl of an RNAase solution (10 mg/ml) for 20 minutes at 50 °C. Thereafter, 1 ml of a 10 % (w/v) SDS (sodium dodecyl sulfate) solution was added to the lysate and the mixture incubated at 70 °C for 30 minutes. The lysate was then cooled to about 45 °C before being added to 0.5 ml of a proteinase K solution (20 mg/ml) which had been prepared extemporaneously. The lysate was then incubated at 45 °C under occasional manual agitation until a transparent solution was obtained. Several phenol extractions were then performed on this transparent solution under the conditions specified in and following the procedures described by (3) at page E.3, until a well-defined interface (as described therein) was obtained. The extracted DNA was then precipitated by adding 20 ml of ethanol. The pellet was recovered by centrifugation at 5000 rpm for 5 minutes and dissolved in 2 ml of TE buffer (pH 8.0).

Cultures of *E. coli*, *B. licheniformis* and *B. subtilis* were grown in L-B medium, either liquid or solid.

"Platings" were performed by : (a) spreading the appropriate dilution of a liquid bacterial culture, essentially under the conditions specified in and following the procedures described by (6) at page 60, on a suitable agar containing medium 15 % (w/v); and (b) growing the resulting plate at 37 °C for 18 hours, in order to obtain isolated colonies of said bacterium.

Isolations of single colonies were done under the conditions specified in, and following the procedures described by (6) at pages 58-60, and general conditions for growth and strain maintenance were performed following the conditions specified in, and following the procedures described by (6) at pages 61-62 and by (4) at pages 5-6.

By the term "transferred", what is referred to is the transferring of a bacterial colony from one culture medium (such as a petrie dish) to another, using standard inoculation techniques, which are well-known to those skilled in the art.

Large scale centrifugations (>100 ml) were carried out using a Beckman centrifuge equipped with a G2-21 rotor. The same centrifuge equipped with a JA-10 rotor was used for all centrifugations of 50-100 ml. Centrifugations of 3-49 ml were performed using this same centrifuge equipped with either a JA-20 or a JA-A rotor. Microcentrifugations (1-2 ml) were carried out using a Sigma 2K15 centrifuge.

Quantitations of DNA were performed following the spectrophotometric determination method as described by (3) at page E.5.

In vitro amplifications of DNA by the polymerase chain reaction (PCR) were carried out under the conditions specified in, and following the procedures described by (3) at 14.18-14.19, as well as the detailed protocols available in the PCR amplification Kits purchased from Biolabs.

Transfers of DNA fragments from agarose gels to nitrocellulose membranes (for Southern blotting experiments) were performed under the conditions specified in, and following the procedures described by (3) at page 9.38-9.39.

Southern Blotting Techniques were performed under the conditions specified in, and following the procedures described by (3) at page 9.31.

Hybridizations of radiolabeled probes to the DNA transferred to the nitrocellulose filters was done under the conditions specified in, and following the procedures described by (3) at 9.52-9.55.

Nucleotide sequencings were performed using the general chain termination dideoxy procedure under the conditions specified in, and following the procedures described by Sanger, et al., (1977) Proc. Natl. Acad. Sci. U.S.A., 74, 5463-5467, with the use of synthetic oligonucleotides serving as the primers for the DNA polymerase reactions.

Preparations of the dideoxy-mediated reactions using the T7 DNA polymerase were performed under the conditions specified in, and following the procedures described by the T7 sequencing Kit manual from Pharmacia LKB Biotechnology. The templates used for the reactions were double-stranded plasmids isolated by large scale plasmid preparation using CsCl gradient centrifugation, as described above. The templates used in the sequencing reactions were denatured by treatment with NaOH as described in the T7 sequencing Kits.

Sequencing strategies used were direct strategies using progressive oligonucleotides as is described by (3) at pages 13.15 and 13.17 (figure 13.3B).

Loading and running of the sequencing gels, as well as submitting them to autoradiography and reading, were performed under the conditions specified in, and following the procedures described by (3) at page 13.54-13.58.

Site-directed mutageneses were carried out under the conditions specified in, and following the procedures described by Kunkel T.A., (1985) Proc. Natl. Acad. Sci., U.S.A., 82:488-492 as well as by (3) at page 15.74-15.79. The mutageneses were performed using the muta-gene phagemid in vitro mutagenesis Kit purchased from Bio-Rad (No. 170-3576). The procedure consists of an elongation of a mutagenic synthetic oligonucleotide using, as a template, a single-stranded uracylated DNA, which is synthesized from the phagemid vector.

Determinations of the quantity of secreted proteins corresponding to given enzymes were performed by submitting the culture supernatant to polyacrylamide gel electrophoresis (PAGE) analysis in the presence of sodium dodecyl sulfate (SDS) in order to separate the various polypeptide components, as follows : A sample of 1 ml of the culture supernatant was precipitated by addition of 7 % (w/v) trichloroacetic acid (TCA), and incubated for 1 hour at 0 °C. The precipitated proteins were then collected by centrifugation at 15,000 RPM for 10 minutes, and the pellet was dissolved in 1 ml of sample buffer consisting in 10 mM Tris/HCl (pH 8.0), 1 mM EDTA, 2.5 % (w/v) SDS, 5 % (v/v) β -mercaptoethanol, and 0.001 % (w/v) bromophenol blue. The resulting suspension was appropriately (see herebelow) diluted with the sample buffer and denatured at 98 °C for 15 minutes. Insoluble materials were then removed by centrifugation at 15000 RPM for 5 minutes. The resulting samples were then submitted to SDS-PAGE analysis using a PhastSystem purchased from Pharmacia LKB Biotechnology, under the conditions specified in, and following the procedures described by Pharmacia in the Separation Technique File No. 110, using a 10-15 % (w/v) polyacrylamide gradient. The gels were run for 60 Vh with a maximum voltage of 250 volts, a maximum power of 3 watts and a maximum intensity of 10 mA. After separation of the polypeptides, the gels were stained with Coomassie blue as described in the Development Technique File No. 200 from Pharmacia. The stained gels were then submitted to densitometry scanning using a laser densitometer (XL) purchased from Pharmacia LKB Biotechnology. The amount of protein in the stained band which corresponded to the enzyme of interest, was determined by comparison with a Bovine serum albumin (BSA) standard, which was run in parallel. The bands exhibiting the following apparent molecular weights were considered for the various enzymes analyzed :

Xylanase	26 kDa
Pullulanase	110 kDa
Subtilisin 168	28 kDa
Subtilisin Carlsberg	28 kDa

The dilutions of the supernatant samples which were submitted to PAGE/densitometry analysis were adjusted so that approximately the same peak area was measured for the samples and the BSA standard. Background values were subtracted from each sample. The background values were estimated from control experiments consisting in analysing in parallel, a supernatant from the corresponding host bearing the control vector pUB131, instead of the expression vector.

Dilutions, quantities, etc. which are expressed herein in terms of percentages are, unless otherwise specified, percentages given in terms of per cent weight per volume (w/v). As used herein, dilutions, quantities, etc., which are expressed in terms of % (v/v), refer to percentage in terms of volume per volume.

Temperatures referred to herein are given in degree centigrade (°C).

The restriction enzyme sites which are identified by the restriction enzyme name followed by a number in brackets ([]) refer to the first nucleotide position, in the sequence of the plasmid (or fragment), by reference to the figures, which is recognized by the restriction enzyme.

Deductions of the amino acid distribution, molecular weight and pI were all performed with the use of IntelliGenetics Suite software for Molecular Biology (Release #5.4) by IntelliGenetics, Inc., U.S.A.

The given sizes of DNA fragments obtained by restriction digestions is defined by the difference between the two nucleotide positions corresponding to the restriction sites.

Having thus described various methods to produce and obtain the xylanase of the present invention from various hosts, methods for the isolation and purification of the xylanase gene, the construction of expression vectors and expression hosts for expressing the xylanase and the use of the xylanase as an enzymatic pretreatment for the biobleaching of pulps (and, in particular wood pulps), the following examples are now presented for the purposes of illustration only and are neither meant to be, nor should they be read as being restrictive.

Example 1

Production of *Bacillus pumilus* PRL B12 Xylanase

A culture of *Bacillus pumilus* PRL B12 was obtained from the American Type Culture Collection, Rockville, Maryland, U.S.A., under accession number ATCC 55443.

A culture of *Bacillus licheniformis* SE2 delap1 was obtained in the manner described below in Example 28.

EP 0 634 490 A1

An agar medium was prepared comprising 1000 ml of Luria and Bertani medium and 0.5 grams of AZCL-xylan.

Starting from a frozen cellular suspension of each of the cultures, two sterile inoculation flasks (flask A and flask B) containing the agar culture medium were inoculated by streaking, each with one of the respective suspensions. In this manner, flask A was inoculated with the *B. pumilus* PRL B12 while flask B was inoculated with the *B. licheniformis* SE2 delap1. The inoculated flasks were then incubated for twenty-four (24) hours, flask A at 30 °C and flask B at 37 °C, so that respective cultures of the *B. pumilus* and the *B. licheniformis* strains were obtained therein.

A preculture medium was prepared comprised of : 5 grams Bacto-Peptone; 5 grams yeast extract; 5 grams glucose; and 1000 ml of phosphate buffer (50 mM, pH 7.0). The preculture medium was then sterilized.

A pair of sterile 250 ml Erlenmeyer Flasks (Preculture Flask #1 and Preculture Flask #2) were each filled with fifty (50) ml of the preculture medium. Preculture Flask #1 was then inoculated with the *B. pumilus* PRL B12 from the culture of flask A. Similarly, Preculture Flask #2 was inoculated with the *B. licheniformis* SE2 delap1 from the culture of flask B. These two preculture flasks were then incubated at 30 °C for 16 to 24 hours (with twenty-four hours being preferable) under agitation (orbital movement of 250 revolutions per minute with approximately 2.54 cm amplitude). At the end of incubation, the presence of a culture of the *B. pumilus* PRL B12 strain was visually observed in Preculture Flask #1 and the presence of a culture of the *B. licheniformis* SE2 delap1 strain was visually observed in Preculture Flask #2. The identity of these cultures was confirmed by standard detection techniques.

The *B. licheniformis* SE2 delap1 strain was then transformed with the pUB-BPX12 expression vector for xylanase (which had been constructed as was described below in Example 17), to form *B. licheniformis* SE2 delap1 (pUB-BPX12) and respective transformants were selected, isolated and purified, as is described below in Example 29.

B. pumilus PRL B12 and *B. licheniformis* SE2 delap1 (pUB-BPX12) each grow best in different culture media. In addition, each of these strains will not grow satisfactorily in the culture medium in which the other strain grows best. Thus, two (2) different culture media (designated herein as "M1" and "M2") were prepared, as follows :

(1) M1 Culture Medium comprised of 60 grams of wheat bran; 13 grams of soluble corn germ extract; 1 gram of sodium chloride; and 1000 ml of deionized H₂O.

(2) M2 Culture Medium comprised of 30 grams of soya flour; 75 grams of soluble starch; 2 grams of sodium sulfate; 5 milligrams of magnesium chloride; 3 grams of NaH₂PO₄; 0.2 grams of CaCl₂·H₂O; and 1000 ml H₂O. The pH of the suspension is adjusted to 5.8 with 10N NaOH.

The M1 culture medium is a medium in which the *B. pumilus* PRL B12 strain grows well. The M2 culture medium is a medium in which the various *B. licheniformis* SE2 delap strains grow well.

The culture broths were then sterilized.

A pair of sterilized one liter agitation flasks, each of which is equipped with (four) bafflers (said flasks hereinafter being designated as Culture Flask #1 and Culture Flask #2), were then filled with the culture media, as follows : Culture Flask #1 was filled with 100 ml of the M1 culture medium; and Culture Flask #2 was filled with 100 ml of the M2 culture medium.

Culture Flask #1 was then inoculated from the culture of *B. pumilus* PRL B12 of Preculture Flask #1, and Culture Flask #2 was inoculated from the culture of *B. licheniformis* SE2 delap1 (pUB-BPX12) of Preculture Flask #2. In doing so, the culture medium in the culture flasks was inoculated with 1 % (volume/volume) of the culture material in the Preculture Flasks. That is to say, Culture Flasks containing 100 ml of the culture medium are inoculated with 1 ml of culture material from the Preculture Flasks.

The Culture Flasks containing the M1 and M2 culture media were then incubated at 30 °C for 72 hours under agitation (orbital movement of 250 revolutions per minute with approximately 2.54 cm amplitude).

Incubation of the Culture Flasks, as outlined above, results in, inter alia, the extracellular production of xylanase. Such xylanase is secreted into the culture broths in the Culture Flasks #1 and 2. The presence of such xylanase in the culture broths was then tested for by specifically assaying the culture broths for xylanase enzymatic activity, as is set forth below in Example 2.

Example 2

Assaying Culture Broth For Xylanase Activity

Determination of the xylanase activity in the culture broths was obtained by use of the XU (Xylanase Unit) method. In this method, the presence and measurement of xylanases in the culture broths is

determined by assaying for the reducing sugars that are released from a xylan substrate (such as birch xylan) as a result of the xylanolytic activity of the xylanases in the respective culture broths. The determination (measure) of the concentration of reducing sugars liberated was carried out following the Somogyi-Nelson methods as described in J. Biol. Chem., 153 (1944) pp. 375-380 and J. Biol. Chem. 160 (1945) pp. 61-68.

Unless otherwise indicated, the buffers mentioned in this example were prepared according to the procedures described by Gomori, Method. Enzymol., Vol. 1, pps. 138-146. The Somogyi Reagent and the Nelson Reagent were prepared as is described in J. Biol. Chem., 153 (1944) pp. 375-380 and J. Biol. Chem. 160 (1945) pp. 61-68. The substrate was prepared by dissolving 20 grams of xylan (ROTH Atr. 7500) in one liter of a 50 mM glycerophosphate buffer (pH 6.0). This solution was then incubated for 10 minutes at 95 °C and manually agitated to obtain a homogenous xylan suspension.

Assays were performed on the *B. pumilus* PRL B12 culture broth in culture flask #1 (the M1 culture medium), and on the *B. licheniformis* SE2 delap1 (pUB-BPX12) culture broth in culture flask #2 (the M2 culture medium) using 0.1 ml of substrate (preincubated to 50 °C) which had been heated before use, as described above. To this substrate, 0.1 ml of the respective culture broths having the xylanase (with an activity of between 0.2 and 0.6 XU/ml) therein (which had been preincubated to 50 °C) were added and the solutions mixed by manual shaking. The assay was then run for fifteen minutes at 50 °C. The reaction was then stopped by adding to the mixture 0.3 ml of 0.5N NaOH.

Blanks were prepared for each dilution of the enzyme by adding 0.3 ml of 0.5N NaOH before the substrate.

Standards were prepared by replacing the 0.1 ml of culture broth having the xylanase therein with 0.1 ml of a series of glucose dilutions having concentrations of from 0 to 5.555 micro-moles (μ M) of glucose per ml, of solution.

As used herein and throughout the remainder of the Examples herein, one XU (Xylanase Unit) is defined as being the amount of xylanase which, under the conditions of the assay, catalyzes the liberation of reducing sugars equivalent, in reducing power, to 1 micromole (μ M) of glucose per minute.

The results of the above assays revealed an activity for the xylanase secreted into the culture broth (of Culture Flask #2) by *B. licheniformis* SE2 delap1 (pUB-BPX12) that was at least fifteen times higher than the activity for the xylanase secreted into the culture broth (of Culture Flask #1) by *B. pumilus* PRL B12.

Example 3

Isolation and Purification of Xylanase from Culture Broth

The xylanase was isolated and purified from the culture broth by starting from respective 100 ml samples of culture mixture obtained from Culture Flasks #1 and #2, as noted above in Example 1.

Approximately 100 ml of the fermentation broth from each of the flasks #1 and #2 were placed in respective test flasks #1 and #2. To each test flask, a respective quantity of filter aid and PERLITE F50 was added up to a concentration of 5.4 % (weight/volume).

The fermentation broths in the test flasks were then paper filtered using a Buchner filtration funnel. Approximately 38 ml of (liquid) filtrate was thus obtained from each filtration, as well as filter cakes. Each of the filter cakes was then washed with deionized water until respective final volumes of 100 ml of filtrate were obtained.

The filtrates obtained were then concentrated on an Amicon ultrafiltration cell (Series 800 stirred cell with an YM10 membrane having a 10 kD cutoff). The concentrate activity was then measured.

1 ml of each of these concentrated samples were then loaded on respective Sepharose Mono-Q HP 16/10 anion-exchange columns equilibrated with a 20 mM TRIS buffer (pH 8.0). The elution was carried out using a flow rate of 3 ml/min of a 20 mM tris(hydroxymethyl)amino-methane (TRIS) buffer (pH 8.0) of linearly increasing NaCl concentration of from 0 to 1 molar. This led to the elutions of the xylanase activity directly after the dead volume on the column into a volume of 15 ml. Respective fractions were then obtained.

1 ml of each of these fractions were then placed on respective Phenyl Sepharose 16/10 columns equilibrated with a 20 mM glycine buffer (pH 9.0), 1M $(\text{NH}_4)_2\text{SO}_4$. The elutions were carried out by means of a descendant gradient by ammonium sulfate into this same buffer, from 1M to 0M in ten (10) minutes, followed by an isocratic elution with a delivery of 5 ml/min. In each column, the xylanase activity was eluted in one fraction after 20 to 21 minutes. These purified, eluted fractions were found to be electrophoretically homogeneous.

Example 4

Amino Acid Sequence

The amino acid sequence of the xylanase of the present invention was indirectly determined by deduction from the nucleotide sequence of the gene that encodes therefor (which gene was obtained and sequenced, as shall be discussed at length below in Example 17).

In order to determine the correct reading frame, the N-terminal sequences of the xylanase of the fractions obtained (as described above in Example 3) from both the B. pumilus strain and the B. licheniformis strain were determined following the protocol set forth in Vandekerckhove, J., et al., Eur. J. Biochemistry, 152, 9 (1985). These N-Terminal sequences were found to be identical, as follows :

SEQ ID NO: 2

Glu-Thr-Ile-Tyr-Asp-Asn-Arg-Ile-Gly-Thr-His-Ser-Gly-Tyr-Asp

Using the N-terminal sequences to determine the correct reading frame, we found that the precursor xylanase of the present invention is comprised of two hundred and twenty-seven (227) amino acids residues (see Figures 1a and 1b) SEQ ID NO:1. Twenty-seven (27) of these amino acids are in the "pre" sequence. The remaining two hundred (200) of these amino acids are the mature protein. This is the same whether this gene is homologously expressed by B. pumilus PRL B12 or heterologously expressed by a recombinant host that has been transformed therewith, such as the deleted B. licheniformis SE2 delap (pUB-BPX12) strains.

The amino acid sequence deduced for the xylanase of Bacillus pumilus PRL B12 (as seen in Figures 1a and 1b) is quite different from those deduced for the xylanases secreted by either B. pumilus IPO or B. pumilus DSM 6124.

Example 5

Amino Acid Distribution

The amino acid distribution of the xylanase of the present invention was indirectly determined from the amino acid sequence of the xylanase (as was indirectly determined, as described above in Example 4).

Examination of the amino acid distribution of the 200 amino acids that comprise the "mature" xylanase protein reveals an enzyme which is rich in tyrosine, threonine and asparagine, as follows :

TABLE 2

Amino Acid Distribution of the "Mature" Xylanase		
Amino Acid	Quantity	Percentage of Molecular Weight
Tyrosine	16	11.6
Threonine	19	8.5
Asparagine	16	8.1
Serine	18	7.0
Lysine	11	6.3
Glycine	22	5.6
Arginine	8	5.4
Phenylalanine	8	5.2
Glutamic Acid	9	5.2
Isoleucine	10	5.0
Leucine	10	5.0
Tryptophan	6	5.0
Aspartic Acid	7	3.6
Valine	8	3.5
Methionine	6	3.5
Glutamine	6	3.4
Alanine	10	3.2
Histidine	4	2.4
Proline	5	2.2
Cysteine	1	0.5
Aspartic Acid & Asparagine	0	0.0
Glutamine & Glutamic Acid	0	0.0

Such an amino acid distribution is quite different from those reported for the xylanases produced by B. pumilus IPO and B. pumilus DSM 6124.

Example 6

Molecular Weight Deduction From Amino Acid Distribution

The deduction of the molecular weight of the xylanase of the present invention was indirectly determined (calculated) from the amino acid distribution noted above in Table 2. This deduction gave the xylanase of the present invention a molecular weight of 22,534.55 Daltons (D).

Example 7

Molecular Weight Determination by SDS-PAGE Analysis

Each of the samples used herein for determination of molecular weight were obtained from the purified fractions of Example 3.

An estimation of the molecular weights of the purified xylanase samples of the present invention by the use of SDS-PAGE analysis was effectuated in denaturing conditions on polyacrylamide gel using Pharmacia PhastGel 10-15 % (w/v) and 20 % (w/v) gels.

Pharmacia LMW markers were used for establishing the relation of molecular weight to migration distance. One vial diluted in 1.5 ml of the following buffer, which was also used for the samples : 10 mM TRIS (pH 8); 1 mM EDTA; 2.5 % (w/v) SDS; 5 % (v/v) beta-mercaptoethanol and 0.1 % (w/v) bromophenol blue.

The samples were each precipitated with trichloroacetic acid before being diluted to a concentration of approximately 100 µg protein/ml (assay : modification of the Bradford Coomassie Blue Binding Assay, described by Read and Northcote, Analytical Biochem., 116:53-64) in the same buffer, noted above, as was used to dilute the markers. The diluted samples were then denatured at 98 °C for fifteen (15) minutes and 4 µl were deposited on the gels. The gels were run for 60 Vh with a maximum voltage of 250 volts, a

EP 0 634 490 A1

maximum power of 3 watts and maximum intensity of 10 mA.

The results of this SDS-PAGE analysis can be seen by reference to the graph in figure 2, where the migration distance from the anode is plotted. In both cases (10-15 % and 20 % gels), the xylanase samples from the native *B. pumilus* PRL B12 strain and the recombinant *B. licheniformis* SE2 delap1 (pUB-BPX12) strain have exactly the same electrophoretic mobility. Furthermore, in both cases, the apparent molecular weight was found to be 26 kD.

Example 8

Prediction of pI From Amino Acid Sequence

Prediction of the isoelectric point (pI) of the xylanase of the present invention from the amino acid sequence noted in Figures 1a and 1b. This deduction gave the xylanase of the present invention an isoelectric point of 9.56.

Example 9

Determination of pI by Isoelectric Focusing Analysis

Each of the samples used herein for determination of isoelectric point (pI) were obtained from the purified fractions of Example 3.

This determination was effectuated by isoelectric focalization in polyacrylamide gels, by employing Pharmacia DryIEF Gels, that had been rehydrated with 2 ml of an ampholine solution (1 volume Pharmacia 8-10.5 % (w/v) ampholine added to 15 volumes of deionized water), following the protocol recommended by the supplier.

A 4 μ l aliquot of each of the enzyme dilutions in H₂O, containing approximately 100 μ g of xylanase were deposited and loaded (200 V, 15 Vh) in the middle of the gels after the prefocusing had taken place (2000 V, 75 Vh). Pharmacia high pI markers were used as standards.

After focusing, gels were stained with Coomassie Blue following the protocol detailed in the Separation Technique File No. 101 (publication 18-1018-20, Pharmacia LKB Biotechnology).

Using this technique, the value of the isoelectric point of the xylanase secreted from *B. pumilus* PRL B12, as well as that xylanase secreted from *B. licheniformis* SE2 delap1 (pUB-BPX12) was determined to be from 9.8 to 9.9. Further, their behavior is the same. The results of this analysis can be seen by reference to figure 3.

Example 10

Determination of Optimum Temperature for Xylan Hydrolysis

Each of the samples used herein for determination of optimum temperature were obtained from the purified fractions of Example 3.

Eighteen (18) samples, each of which contain a 1 % (w/v) birchwood xylan substrate (Roth, Atr. 7500), were dissolved in 50 mM of glycerophosphate buffer (pH 6.5).

Assays on each of the samples were then performed with an incubation time of 15 minutes. These assays were conducted on pairs of samples at different temperature increments of 5 °C starting at 40 °C and finishing at 80 °C. The amount of reducing sugars released gives an indication of the activity of the xylanase sample being assayed. The quantity of reducing sugars liberated was measured following the Somogyi-Nelson method as described in Example 2.

The results of these assays, given as percentages of the maximal activity, is given in Table 3, as follows :

TABLE 3

5	Optimum Temperature Determination		
	Temperature (°C)	% Maximum Activity	
		Xylanase from <i>B. pumilus</i> PRL B12	Xylanase from <i>B. licheniformis</i> SE2 delap1.
	40.0	54.4	51.2
	45.0	62.2	62.4
10	50.0	81.5	81.4
	55.0	100.0	100.0
	60.0	94.0	84.7
	65.0	79.7	81.3
	70.0	32.5	31.1
15	75.0	20.5	24.4
	80.0	12.2	11.4

Conducting the aforementioned tests gave results that show that the optimum temperature of the xylanase of the present invention is 55 °C.

Example 11

Determination of Range of Temperature Stability

Each of the samples used herein for determination of the range of temperature stability of the xylanase of the present invention were obtained from the purified fractions of Example 3 and prepared as described in Example 10.

Assays on each of the samples were then performed after the preincubation times (in minutes) and at the temperatures noted below in Table 3. The activity of these samples was determined at 0, 10, 30, 60 and 120 minutes following the protocol set forth above in Example 2.

The results of these assays, given as percentages of the maximal activity, is given in Table 4, as follows :

35	Determination of Range of Temperature Stability			
	Time (Minutes)	% Maximum Activity		
		50 °C	60 °C	70 °C
	0	100.0	100.0	100.0
40	10	111.0	80.0	0.0
	30	113.0	68.0	0.0
	60	119.0	52.0	0.0
	120	110.0	40.0	0.0

Conducting the aforementioned tests gave results that show that, at 50 °C, the xylanase of the present invention is fully stable for at least 120 minutes.

Example 12

Determination of Optimum pH for Xylan Hydrolysis

Each of the samples used herein for determination of optimum pH were obtained from the purified fractions of Example 3, and prepared as described in Example 10.

Assays on each of the twenty-two samples (adjusted to the different pH values noted below in Table 5) were performed at 50 °C (the correction for pH/temperature relationship is negligible with this buffer) with an incubation time of 15 minutes following the protocol set forth above in Example 2. The amount of reducing sugars released gives an indication of the activity of the xylanase sample being assayed. The

quantity of reducing sugars liberated was measured following the Somogyi-Nelson method as described in Example 2.

The results of these assays is given in Table 5, as follows :

pH	Optimum pH Determination	
	% Maximum Activity	
	Xylanase from <i>B. pumilus</i> Strain	Xylanase from <i>B. licheniformis</i> Strain
5.0	45.4	45.1
5.5	78.6	78.3
6.0	98.7	93.2
6.5	96.6	100.0
7.0	100.0	96.1
7.5	82.2	86.2
8.0	73.8	63.7
8.5	52.7	44.6
9.0	24.6	18.8
9.5	11.0	4.7
10.0	0.4	2.0

Conducting the aforementioned tests gave results that show that the optimum pH of the xylanase of the present invention is 6.5-7.0.

From all of the foregoing Examples, it is evident that the xylanase of the present invention is the same, regardless if it was expressed by the natural source thereof (*B. pumilus* PRL B12) or by the recombinant host, *B. licheniformis* SE2 delap1 (pUB-BPX12). It further appears that the xylanase of the present invention has an amino acid sequence and distribution that is different from those of other xylanases, even those xylanases produced by other strains of *B. pumilus*.

Example 13

Effect of pH on the Efficacy of Xylanase Pretreatment

Eight suspensions of a softwood kraft pulp were prepared, each having an initial Kappa Index of 25.5 and a consistency (Con.) of 2.5 %. Six of these suspensions were pretreated for two hours at 50 °C with 30 XU of the xylanase of the present invention per gram of dry pulp to be pretreated therewith. Two additional suspensions of the kraft wood pulp were subjected to the same conditions, but in the absence of any xylanase whatsoever. These pretreated kraft pulp samples were then, without intermediate washing, subjected to chlorination (C) by use of the weight of chlorine (given in terms of active chlorine multiples), specified below in Table 6A followed by an alkaline extraction (E).

Twenty-four suspensions of a hardwood kraft pulp were prepared having an initial Kappa Index of 13 and a consistency of 2.5 %. These suspensions were pretreated for two hours at 50 °C with 30 XU of the xylanase of the present invention per gram of dry pulp to be pretreated therewith. These pretreated kraft pulp samples were then, without intermediate washing, subjected to chlorination (C) at 22 °C for 1.0 hours and a consistency of about 3 % followed by an alkaline extraction (E) at 60 °C for 1.5 hours and a consistency of 5 % (see Table 6B).

The different treatment pH's were obtained by small additions of diluted acid (.1N), such as sulfuric acid. The treatment at pH 9.5 substantially corresponds, in fact, to actual industrial situations wherein the pH is not regulated, the pulp being suspended in nonbuffered water (this test is marked in Table 6A by the asterisk).

The results of the pretreatments are set forth below in Tables 6A and 6B :

TABLE 6A

Effect of pH on Efficacy of Pretreatment with <i>B. pumilus</i> PRL B12 Xylanase in Classical Bleaching Sequences			
Softwood Kraft Pulps			
Initial pH	XU/g	Multiple	Kappa Index
6.5	30	0.17	7.40
7.0	30	0.17	6.71
8.0	30	0.17	6.56
8.5	30	0.17	6.30
9.0	30	0.17	6.57
9.5*	30	0.17	7.38
9.5	0	0.17	10.00
9.5	0	0.20	7.00

TABLE 6B

Effect of pH on Efficacy of Pretreatment with <i>B. pumilus</i> PRL B12 Xylanase in Classical Bleaching Sequences			
Hardwood Kraft Pulps			
Kappa Index			
Initial pH	0 XU/g Multiple: 0.20	5 XU/g Multiple: 0.12	10 XU/g Multiple: 0.12
6.5	2.40	2.25	2.19
7.0	2.15	2.22	2.08
7.5	2.10	2.16	2.08
8.0	2.16	2.18	2.13
8.5	2.16	2.22	2.24
9.0	2.13	2.32	2.38
9.5	2.11	2.54	2.54
10.0	2.09	2.56	2.68

Surprisingly, (and in contrast to the results seen in Example 12 and Table 5, wherein when determined on a purified substrate the optimal pH is only about 7.0), as demonstrated herein, in biobleaching conditions, the optimum pH of the xylanase appears to be about 8.5 when softwoods are involved and about 7.5-8.0 when hardwoods are involved.

Furthermore, and perhaps more surprisingly, it is noted that the xylanase of the present invention is efficient for facilitating the delignification of wood pulps having all pH's in the 7-9.5 range (the natural pH of this kraft pulp in a water suspension).

The obtained effects seen in Tables 6A and 6B are also significant in that the enzymatic treatment permits (in pH's of 6.5-9.5) a 15 % reduction in the chlorine which is needed to be used for the chemical-treatment of softwoods in the delignification stage and a 40 % reduction in the chlorine which is needed to be used for the chemical-treatment of hardwoods in the delignification stage.

5

Example 14

Effect of Xylanase Concentration on the Efficacy of Xylanase Pretreatment

10 A Kraft hardwood pulp was pretreated with an oxygen treatment according to the process described at length in United States Letters Patent No. 4462864, so as to produce an oxygen-treated pulp having an initial Kappa Index of 12.3 and an initial *ISO of 33.4.

Six (6) suspensions (samples) were then prepared from the oxygen-treated pulp.

15 The operating conditions used were those which would be possible to utilize industrially (50 °C for one hour at a consistency of 5 %). The general scheme of the bleaching sequence (C/D)EDPD was thereafter performed with the pulp sample.

Two (2) of the samples (designated samples 1 and 2) were then selected as reference bleaching sequences and were effectuated by placing in operation one (1) dose of active chlorine equal to 0.2 times the Kappa Index during the course of the C/D step. This dose was then retaken in 80 % gaseous chlorine and 20 % in chlorine dioxide. Larger doses of chlorine dioxide were used for covering a realistic range of final whiteness.

20 The remaining four (4) samples were selected to be subjected to an enzymatic pretreatment that was realized by the use of either 8 (samples 3 and 4) or 13 (samples 5 and 6) Xylanase Units (XU) per gram of dry pulp. We note that the bleaching sequence immediately following the enzymatic pretreatment was performed without any intermediate washing. The active chlorine multiples used were from 0.16 to 0.14 (representing an economy of elemental chlorine -- ClO_2 in the chlorination stage being kept constant -- of, respectively, 25 % and 38 %). These reductions were obtained by reducing the dose of molecular chlorine, the dose of chlorine dioxide remaining the same.

25 The starting *ISO of these samples was 33.4. The starting Kappa Index was 12.3. Full details of operating conditions and the results of the various trials of this Example can be seen by reference to Table 7.

35

40

45

50

55

TABLE 7

Efficacy of <i>B. pumilus</i> PRL B12 Xylanase Pretreatment in Classical Bleaching Sequences											
Sample	Step	Reactants (g/100g o.d.p.)				Temp °C	Time (Hr)	Con. (%)	pH		°ISO
		Cl ₂	NaOH	ClO ₂	H ₂ O ₂				Start	End	
1-2	X	----	---	---	---	--	---	--	----	----	----
		0 XU/g o.d.p.									
	C/D	1.96	---	0.5	---	40	0.5	3	2.2	2.1	----
	E	----	2.0	---	---	70	1.5	12	12.7	11.4	53.4
		Kappa Index : 2.6									
1	D	----	---	0.6	---	75	3.0	12	5.6	4.4	75.8
	P	----	0.6	---	0.2	70	1.5	12	12.0	10.7	81.5
	D	----	---	0.3	---	85	2.5	12	5.5	4.8	88.0
2	D	----	---	0.9	---	75	3.0	12	5.5	3.6	77.4
	P	----	0.6	---	0.2	70	1.5	12	12.0	10.6	82.4
	D	----	---	0.3	---	85	2.5	12	6.0	4.9	89.0
3-4	X	----	---	---	---	50	1.0	5	7.0	7.0	----
		8 XU/g o.d.p.									
	C/D	1.22	---	0.5	---	40	0.5	3	3.0	3.0	----
	E	----	2.0	---	---	70	1.5	12	12.5	11.6	54.3
		Kappa Index : 3.2									
3	D	----	---	0.6	---	75	3.0	12	5.0	4.4	72.2
	P	----	0.6	---	0.2	70	1.5	12	11.7	10.7	79.8
	D	----	---	0.3	---	85	2.5	12	5.6	4.9	87.4

TABLE 7 (suite)

Efficacy of <i>B. pumilus</i> PRL B12 Xylanase Pretreatment in Classical Bleaching Sequences											
		Reactants (g/100g o.d.p.)				Temp	Time	Con.	pH		
Sample	Step	Cl ₂	NaOH	ClO ₂	H ₂ O ₂	°C	(Hr)	(%)	Start	End	°ISO
4	D	----	---	0.9	---	75	3.0	12	5.0	3.6	72.8
	P	----	0.6	---	0.2	70	1.5	12	11.7	10.7	81.4
	D	----	---	0.3	---	85	2.5	12	5.7	5.0	88.7
5-6	X	----	---	---	---	50	1.0	5	7.0	7.1	----
	13 XU/g o.d.p.										
	C/D	1.22	---	0.5	---	40	0.5	3	3.1	3.1	----
E	E	----	2.0	---	---	70	1.5	12	12.5	11.4	55.0
	Kappa Index : 3.0										
5	D	----	---	0.6	---	75	3.0	12	5.0	4.3	72.2
	P	----	0.6	---	0.2	70	1.5	12	11.9	10.6	80.1
	D	----	---	0.3	---	85	2.5	12	5.7	4.8	88.2
6	D	----	---	0.9	---	75	3.0	12	5.0	3.6	72.6
	P	----	0.6	---	0.2	70	1.5	12	11.9	10.6	81.7
	D	----	---	0.3	---	85	2.5	12	5.7	4.9	89.3

As can be seen from the above, use of the xylanase of *B. pumilus* PRL B12 is efficient for the pretreatment (biobleaching) of wood pulp in classical bleaching sequences. First, it is noted that use of the xylanase as a pretreatment permitted a substantial reduction in the active chlorine used in the chemical-treatment step of the delignification stage. Second, after the delignification stage, the Kappa Index of each of the samples noted above, was greatly reduced (from 12.3 to 3.0-3.2), thereby indicating that use of this xylanase as a pretreatment permits wood pulp to be obtained that has an acceptably-low lignin content (as measured by the Kappa Index of the wood pulp).

Example 15

Effect of Xylanase Pretreatment in ECF Sequences

From the oxygen-treated hardwood pulp of Example 14, six suspensions (samples) were prepared. Three (3) of these samples (designated samples 4, 5 and 6) were, first, subjected to an enzymatic treatment without washing between enzymatic treatment and the first dioxide chlorination. All of the samples were then subjected to an ECF bleaching sequence of the type DPDPD. These ECF sequences were performed

using increasing weights of chlorine dioxide.

Full details of the operating conditions and the results of the various trials of these samples can be seen by reference to Table 8.

TABLE 8

Efficacy of <i>B. pumilus</i> PRL B12 Xylanase Pretreatment in Elemental Chlorine Free Bleaching Sequences											
Sample	Step	Reactants (g/100g o.d.p.)			Temp °C	Time (Hr)	Con. (%)	pH		Kappa	
		ClO ₂	H ₂ O ₂	NaOH				Start	End	°ISO	Index
1-3	D	2.0	---	---	60	0.5	3	3.6	3.5	----	---
	P	---	0.5	2.0	70	1.5	12	12.2	11.5	68.9	5.5
1	D	0.4	---	---	75	3.0	12	5.7	5.3	79.5	---
	P	---	0.2	0.6	70	1.5	12	12.0	11.0	82.3	---
	D	0.3	---	---	85	2.5	12	5.9	5.0	86.0	---
2	D	0.6	---	---	75	3.0	12	5.4	4.8	79.4	---
	P	---	0.2	0.6	70	1.5	12	12.0	11.0	83.0	---
	D	0.3	---	---	85	2.5	12	5.6	4.9	86.6	---
3	D	0.8	---	---	75	3.0	12	6.1	4.6	80.6	---

TABLE 8 (Suite)

Efficacy of <i>B. pumilus</i> PRL B12 Xylanase Pretreatment in Elemental Chlorine Free Bleaching Sequences											
Sample	Step	Reactants (g/100g o.d.p.)			Temp °C	Time (Hr)	Con. (%)	pH		°ISO	Kappa Index
		ClO ₂	H ₂ O ₂	NaOH				Start	End		
15	P	---	0.2	0.6	70	1.5	12	12.0	10.9	84.2	---
	D	0.3	---	---	85	2.5	12	5.5	4.9	87.5	---
20	4-6	X	---	---	50	1.0	5	7.0	7.0	----	---
		8 XU/g o.d.p.									
	D	1.3	---	---	60	0.5	3	3.8	3.8	----	---
25	P	---	0.5	2.0	70	1.5	12	12.5	11.6	66.9	5.9
	4	D	0.4	---	75	3.0	12	5.4	5.0	78.0	---
	P	---	0.2	0.6	70	1.5	12	12.0	10.8	82.4	---
30	D	0.3	---	---	85	2.5	12	5.2	4.5	86.2	---
	5	D	0.6	---	75	3.0	12	5.5	4.6	78.5	---
	P	---	0.2	0.6	70	1.5	12	12.0	10.7	83.6	---
35	D	0.3	---	---	85	2.5	12	5.0	4.2	86.6	---
	6	D	0.8	---	75	3.0	12	5.9	4.6	79.3	---
	P	---	0.2	0.6	70	1.5	12	12.0	10.8	84.3	---
40	D	0.3	---	---	85	2.5	12	5.6	4.8	88.2	---

As can be seen from the above, it is clear that an enzymatic treatment with the use of the xylanase of *B. pumilus* PRL B12 demonstrates good efficiency and efficacy in the pretreatment (biobleaching) of wood pulp in ECF bleaching sequences, permitting a wood pulp to be obtained that has an acceptably-low lignin content, as well as permitting a substantial economy of chlorine dioxide which must be used while still attaining an elevated final whiteness. This is interesting due to the fact that, industrially, the capacity of the chlorine dioxide generator is often limited.

In the above regard, it is noted that after the xylanase treatment step for each of the samples noted above, the Kappa Index was greatly reduced (from 12.3 to 5.9), thereby indicating that the amount of lignin that remained in the pulp, as well as the amount of ClO₂ needed during subsequent steps of the bleaching sequence was greatly reduced.

Example 16

Effect of Xylanase Pretreatment In TCF Sequences

- 5 From the oxygen-treated Kraft hardwood pulp of Example 14, four suspensions (samples) were prepared. Two samples (designated samples 1 and 2) were then used in a totally chlorine free (TCF) bleaching sequence of the type OQPZP (Oxygen, Sequestrant treatment, Peroxide, Ozone, Peroxide). The other two samples were subjected to a totally chlorine free (TCF) bleaching sequence of the type OX/QPZP. The enzyme used in the enzymatic treatment was xylanase derived from B. pumilus PRL B12.
- 10 No washing of the pulp was performed between X and Q, but the pH was adjusted to the values noted in Table 9 below.
- The enzymatic activity utilized was from 10 XU/gram of dry pulp.
- The reactants (with the exception of ozone) used in the steps of the sequences are (in grams per 100 grams of the oven-dried pulp to be treated therewith) as follows : 0 [6 bars O₂, 2.5 NaOH, 0.5 MgSO₄·7H₂O]; X/Q [10 XU/g at pH 7.5, 0.5 % DTPA (40 %) at pH 5.5 (acidification with dilute H₂SO₂); Q [0.5 % DTPA (40 %) at pH 5.5 (acidification with dilute H₂SO₂); P [1.5 H₂O₂, 1.8 NaOH, 0.5 MgSO₄·7H₂O, 2.5 sodium silicate (water-glass quality 38 ° beaumé)]; Z [see Table 9]; P [2.0 H₂O₂, 1.6 NaOH, 1.0 MgSO₄·7H₂O, 3.0 sodium silicate (water-glass quality 38 ° beaumé)]. The operating conditions, the quantity (in grams per 100 grams of oven-dried pulp to be treated therewith) and the results of the various trials of
- 20 these samples can be seen by reference to Table 9.

25

30

35

40

45

50

55

TABLE 9

Efficacy of <i>B. pumilus</i> PRL B12 Xylanase Pretreatment in Totally Chlorine Free Bleaching Sequences									
Sample	Step	O3	Temp °C	Time (min)	Con. (%)	pH		°ISO	Kappa Index
1-2	O	---	120	90	15	12.7	9.6	56.8	7.4
	Q	---	50	30	5	5.5	6.0	----	---
	P	---	70	120	12	11.6	11.2	73.1	6.4
1	Z	0.35	22	2 1/4	40	3.0	3.6	79.7	---
	P	----	80	240	30	~11.0*	9.6	88.8	---
2	Z	0.52	22	3 1/2	40	3.0	3.4	83.1	---
	P	----	80	240	30	~11.0*	9.5	91.0	---
3-4	O	---	120	90	15	12.7	9.6	56.8	7.4
	X/Q	---	50	90	5	7.5	7.6	----	---
	P	---	70	120	12	11.7	10.9	76.0	5.5
3	Z	0.28	22	2 1/4	40	3.0	4.0	81.3	---
	P	----	80	240	30	~11.0*	10.8	89.6	---
4	Z	0.43	22	3	40	3.0	3.9	83.5	---
	P	----	80	240	30	~11.0*	10.4	91.5	---

* These pH's represent approximate values. The actual values range between 10.5 and 11.5.

The results of the above-noted trials clearly show that an enzymatic treatment with the xylanase of the present invention permits an impressive reduction in the quantity of ozone needed to be utilized in a TCF sequence while still producing a higher final whiteness. This represents not only a substantial savings in costly ozone but also reduces the quantity of ozone, which can degrade the pulp, which is employed therein.

Example 17Preparation of Xylanase Expression Vector5 1. Extraction of chromosomal DNA from Bacillus pumilus PRL B12

L-B medium was inoculated with 200 ml of the culture from Flask A (Example 1) and then cultivated in the L-B medium for 16 hours at 37 °C. The DNA was then extracted from the culture as was described above in the section entitled "Methods and Techniques".

10

2. Constructions of a Bacillus pumilus PRL B12 Gene Library

The extracted B. pumilus PRL B12 chromosomal DNA was then partially digested with Sau3AI. The reported quantity of DNA to enzyme used was adjusted in such a manner as to obtain a maximum of chromosomal DNA fragments having sizes of between 2 and 7 kbp (kbp: 10³ base pairs).

15

The DNA fragments obtained were then subjected to 0.8 % (w/v) agarose gel electrophoresis in order to effect a separation of the DNA fragments according to size. The DNA fragments having a size of between 2 and 7 kbp, as identified from the gel electrophoresis, were then isolated and purified using the "Gene Clean" method or the filtration method using centrifugation.

20

The purified DNA fragments were then ligated with plasmid pBR322 which had previously been digested at the BamHI site and then dephosphorylated.

The obtained ligation was then transformed into cells of E. coli MC1061 by electroporation. The transformed E. coli MC1061 cells were then cultured at 37 °C on 1.5 % L-B agar plates supplemented with 100 µg/ml of ampicillin and 0.8 g/l of AZCL-xylan.

25

The resulting colonies constituted the gene library of B. pumilus PRL B12.

3. Screening The Gene library for Recombinant Plasmids Containing the Xylanase Gene of Bacillus pumilus PRL B12

30 After about 24 hours of growth on the plates at 37 °C in the culture media described above, the colonies showing an AZCL-xylan hydrolysis zone were identified and their plasmids analyzed. The plasmids present in these colonies were isolated following the alkaline lysis technique described in (3) at 1.25-1.28.

35

The analysis (by restriction) indicated that various isolated plasmids contained the same xylanase gene, albeit on different sizes of B. pumilus chromosomal fragments. The restriction analysis further indicated that the shortest DNA fragment obtained that included the xylanase gene was approximately 2.7-2.8 kbp in size, being carried by the pBR322 plasmid which had been ligated therewith. This new plasmid was designated pBPX1.

4. Subcloning of Chromosomal Fragment Containing Xylanase Gene

40

The expression vector containing the B. pumilus PRL B12 xylanase gene is pUB-BPX12 (Figure 4). The expression vector was obtained by subcloning of the chromosomal fragment from pBPX1 that contained the xylanase gene.

45

The shuttle vector (E. coli-B. subtilis) pUB131 (obtained as described in European Patent Application No. 90116322.0) was digested at the BamHI site and dephosphorylated.

The recombinant pBPX1 plasmid (obtained as described above) was then subjected to a partial digestion with Sau3AI. The fragments obtained from this digestion were then ligated with the linearized and dephosphorylated pUB131 shuttle plasmid. The obtained ligation was then transformed into E. coli MC1061 cells by electroporation.

50

The transformants were then selected on L-B plates supplemented with 100 µg/ml of ampicillin, 25 µg/ml of kanamycin and 0.8 g/l of AZCL-xylan. After growth for 24 hours at 37 °C, the colonies showing zoning were transferred and reisolated. Plasmid pUBC-BPX12, present in these transformants was then isolated by the alkaline lysis technique. Restriction analysis showed that this isolated plasmid (pUBC-BPX12) includes the xylanase gene on an approximately 1.0 kbp Sau3AI fragment (the expression cassette) of B. pumilus PRL B12 chromosomal DNA.

55

When the plasmid pUBC-BPX12 is reintroduced into the strain E. coli MC1061, all the resulting transformants show large zoning on AZCL-xylan medium, thus demonstrating the good expression of the xylanase gene in E. coli.

pUBC-BPX12 was then used to transform cells of *E. coli* JM109 using the CaCl_2 technique and transformants were selected. One transformant containing plasmid pUBC-BPX12 was isolated and a large scale preparation was carried out in order to determine the nucleotide sequence of the inserted fragment containing the xylanase gene.

The sequencing strategy utilized was a direct strategy using progressive oligonucleotides as described by (3) at page 13.15 and 13.17 (figure 13.3B), using the double-stranded pUBC-BPX12 plasmid as a template.

For initiating the sequence determination, the oligonucleotides were designed to hybridize with the vector pUBC131, in order to determine the nucleotide sequence in both extremities of the approximately 1.0 kbp xylanase fragment. The sequence of these synthetic oligonucleotides is given hereafter :

SEQ ID NO:3	5'-GTAGAGGATCATCATGT-3'
SEQ ID NO:4	5'-TACCTTGTCTACAAACCCC-3'
SEQ ID NO:5	5'-TGAGTTGCTAGTAACATCTCACCGA-3'

The rest of the sequence was determined by using oligonucleotides synthesized according to the newly determined sequence.

The results of this sequenced determination revealed that the xylanase gene had been obtained as a 1022 bp *Sau3AI* fragment which can be seen by reference to figures 1a and 1b (SEQ ID NO:1).

The xylanase gene was then obtained on a 1061 bp *Sall*-*EcoRV* DNA fragment containing the xylanase gene by double digestion of pUBC-BPX12 with *Sall* and *EcoRV*, followed by purification by electrophoresis in agarose gel.

The vector pUB131 was then digested with restriction enzyme at the *EcoRV* and *Sall* sites and the 1061 bp *Sall*-*EcoRV* fragment was ligated therewith.

The resulting ligation was then introduced, following the competent cell technique, into *B. subtilis* SE3 host cells. Transformants were selected on L-B plates supplemented with 25 $\mu\text{g/ml}$ of Kanamycin and analysed by restriction as described above. The resulting plasmid was pUB-BPX12 (figure 4).

Example 18

Preparation of Pullulanase Expression Vector pUBDEBRA1

Expression vector pUBDEBRA1 (Figure 5) is a plasmid which contains the gene coding for pullulanase of *B. deramificans* T 89.117D under the control of its own pullulanase transcription promoter, cloned in the vector pUB131. This plasmid (pUBDEBRA1) is obtained, as described below.

Bacillus deramificans T 89.117D was cultivated in 200 ml of MYE medium composed of K_2HPO_4 33 mM, KH_2PO_4 3H₂O 6 mM, $(\text{NH}_4)_2\text{SO}_4$ 45 mM, $\text{MgCl}_2 \cdot 6\text{H}_2\text{O}$ 1 mM, $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$ 1 mM, yeast extract 0.5 % (w/v), glucose 0.5 % (w/v), pH adjusted to 4.5 with H_3PO_4 . The chromosomal DNA was extracted from this culture and purified as described above in the section headed "Methods and Techniques". A *B. deramificans* gene library was constructed by cloning partial *Sau3AI* fragments in pBR322, as described in example 17 (part 2), except that the size of the partial *Sau3AI* DNA fragments was 5-10 kbp, instead of 2-7 kbp, and the transformed *E. coli* MC1061 cells constituting the library were plated on a different medium : L-B supplemented with 100 $\mu\text{g/ml}$ ampicillin.

The colonies were grown for 18 hours at 37 °C, and transferred to a second plate containing an identical medium. One of the plates was covered with a 1 % agar overlay containing 100 mM sodium acetate (pH 4.5) and 0.1 % AZCL-pullulan. After an incubation at 60 °C for 18 hours, a colony showing a zoning was identified and isolated from the corresponding replicated plate. A plasmid, designated pBRDEBRA3 was isolated from this colony by the small-scale alkaline lysis method described above, and a restriction analysis thereof showed that the plasmid contained an inserted fragment from *B. deramificans* T 89.117D of 9 kbp.

A 4.5 kbp *EcoRI*-*Bam*HI fragment of pBRDEBRA3 was obtained by double digestion of pBRDEBRA3 with *EcoRI* and *Bam*HI and subsequent purification by electrophoresis in a 0.8 % agarose gel. This fragment was then ligated with vector pUB131, which had previously been subjected to a double digestion with *Bam*HI and *EcoRI*, at the *Bam*HI and *EcoRI* sites thereof, using *B. subtilis* PSL1 as a cloning host.

The resulting plasmid pUBDEBRA1 was isolated and purified from the transformed PSL1 cells by the large scale alkaline lysis method. The plasmid preparation was tested for the functionality of the cloned

pullulanase gene by transformation in *B. subtilis* PSL1. All transformants obtained were able to express and secrete the pullulanase gene, since zoning was observed when the colonies were overlaid with AZCL-pullulan.

The transformed *B. subtilis* PSL1 colonies containing pUBDEBRA1 were transferred to a second L-B plate supplemented with 25 µg/ml of Kanamycin. One of the plates was covered with a 1 % agar overlay containing 100 mM sodium acetate (pH 4.5) and 0.1 % AZCL-pullulan. After an incubation at 60 °C for 18 hours, all the transformant colonies showed an AZCL degradation halo.

Example 19

Preparation of Alkaline Protease Expression Vector pKAC1

Expression vector pKAC1 (Figure 6) is a plasmid which contains the gene coding for the alkaline protease of *B. subtilis* 168, under the control of its own promoter, cloned in the vector pUB110. This plasmid (pKAC1) is obtained as described below.

Plasmid pSBT2 was isolated from the chromosomal DNA of *B. subtilis* 168 as follows :

First, the chromosomal DNA was extracted and purified as described in the section entitled "Methods and Techniques". Then, the extracted and purified DNA was then submitted to a restriction digestion with ClaI. The resulting DNA fragments were then separated according to size on an agarose gel (0.8 % w/v) and fragments of 3-5 kbp in size were extracted and purified by the Gene Clean method.

The resulting preparation was then treated with the Klenow fragment of DNA polymerase to fill the 5' protruding ClaI cohesive termini. The resulting DNA preparation was then ligated with vector pMK4, which had been previously digested with SmaI and dephosphorylated. The ligation was transformed into *E. coli* MC1061 by the CaCl₂ technique, and around 1,000 transformant colonies were selected on L-B plates containing 100 µg/ml ampicillin.

The transformant colonies obtained were then pooled by resuspension in 50 ml liquid L-B medium and their plasmid content was extracted using the large scale plasmid preparation method.

This plasmid preparation was then transformed into *B. subtilis* 512 PN⁻ and the transformants plated on protease detection plates. *B. subtilis* 512 PN⁻ is a mutant of *B. subtilis* 168 which produces a small zoning halo on protease detection plates (Millet et al., (1976) Biochimie, 58:109-117). The transformant colonies were then visually inspected for the presence of a halo of a larger size. A colony presenting such a halo was isolated and its plasmid was extracted using the small scale plasmid preparation method described above.

The resulting plasmid, designated pSBT2, was then transformed into *E. coli* JM109 and a large scale plasmid preparation of pSBT2 was made from an *E. coli* transformant. This plasmid preparation of pSBT2 was transformed again into *B. subtilis* 512 PN⁻. All the transformants obtained exhibited a larger halo on protease detection plates than the control strain (*B. subtilis* 512PN⁻ containing vector pMK4), thus showing that the alkaline protease gene was expressed in *B. subtilis* from plasmid pSBT2.

The plasmid pSBT2 was then digested with EcoRI and a 2.7 kbp EcoRI-EcoRI fragment of plasmid pSBT2 was then subcloned into the EcoRI site of the pUB110 plasmid, using *B. subtilis* SE3 as a cloning host. The resulting plasmid is pKAC1 (figure 6).

Example 20

Preparation of Alkaline Protease Expression Vector pLI1

Expression vector pLI1 (figure 7) is a plasmid which contains the entire gene coding for the alkaline protease of *B. licheniformis* SE2 under the control of its own transcription promoter cloned in the vector pUB131. This plasmid (pLI1) is obtained as described below.

The 800 bp DraI-PstI fragment of pKP1, the construction of which is described below in example 23 part 3, was subcloned into the PstI-HincII sites of phagemid pBS-, to create the plasmid pKN8. Plasmid pKN8 was then subjected to a site-directed mutagenesis in order to remove the StyI site using the following synthetic oligonucleotide, which had been previously been extemporaneously prepared :

SEQ ID NO:6 5'-AAGCTTGTATGCCTGCAG-3'

The plasmid created was pKN9.

The vector pUBC134 was then constructed. First, the PstI site of pUBC132 was deleted by removing the 3' protruding terminus by treatment thereof with T4 DNA polymerase as described in (3) at pages F.4-F.5. The resulting plasmid was pUBC133.

EP 0 634 490 A1

The following synthetic double-stranded DNA was constructed and cloned into the SacI-BamHI sites of pUBC133 :

5 SEQ ID NO:7 5' -GATCCCCTTGGCTGCAGGAGCT-3'
 SEQ ID NO:8 3' - GGGAACCGACGTCC -5'

This insertion created the plasmid pUBC134.

10 The plasmid pUBC134C was then constructed by cloning of the 548 bp PstI-SacI fragment of pKC1 (constructed as described below in Example 23, part 2) into the SacI-PstI sites of pUBC134 after double digestion of both pUBC134 and pKC1 with PstI and SacI.

15 The 812 bp BamHI-PstI fragment of pKN9 was obtained by a double digestion of pKN9 with BamHI and PstI. This 812 bp fragment was then cloned into the PstI-BamHI sites of vector pUBC134C. The plasmid generated thereby was the plasmid pLINC, which contains the complete B. licheniformis SE2 alkaline protease gene.

20 The 1001 bp Styl-SacI fragment of pLINC was obtained by a double digestion with Styl and SacI and isolated. This 1001 bp DNA fragment was then subcloned into the SacI-Styl sites of pKPN14, the construction of which is described below in example 25, thereby generating plasmid pKPN15. The pKPN15 transformants were selected using tetracycline selection.

A derivative of plasmid pKPN15 that is able to replicate in B. subtilis and B. licheniformis strains was then constructed by replacing the replication functions for E. coli carried by the 3635 bp SacI-BglII fragment of plasmid pKPN15 with the 2199 bp BglII-SacI fragment that carries the replication functions for Bacillus and which was isolated from plasmid pUB131.

25 The derivative of plasmid pKPN15, referred to above, was constructed by cloning in B. subtilis SE3, the 3402 bp BglII-SacI fragment from pKPN15 into the 2198 bp BglII-SacI vector fragment from pUB131. The resulting plasmid was designated plasmid pLI1 (figure 7).

Example 21

30 Preparation of Alkaline Protease Expression Vector pL7SBT

35 Expression vector pL7SBT (figure 8) was constructed, which contains the sequence coding for the alkaline protease of B. subtilis 168 under control of the transcription promoter of the alkaline protease of B. licheniformis (subtilisin Carlsberg). This plasmid (pL7SBT) is obtained as described below.

1. Preparation of pLI2NC

40 The 1001 bp Styl-SacI fragment of pLINC (constructed as described above in Example 20) was subcloned into the SacI-Styl site of pLID1 (constructed as described below in Example 25), creating the plasmid pLI2NC.

2. Preparation of pBS7MASE

45 The vector pBS5 was created by cloning the following double-stranded synthetic DNA :

50 A 5' -GATCC CC GGGACCT T AGGCCT TTAATTAA CCTTGG CGGCCG CTCGAG GAGCT-3'
 B 3' - G GG CCCTGGA A TCCGGA AATTAATT GGAACC GCCGGC GAGCTC C -5'
 BamHI SmaI PpuMI StuI PacI StyI NotI XhoI SacI
 A = SEQ ID NO:9
 B = SEQ ID NO:10

55 into the BamHI-SacI sites of pBS-, forming pBS5. The 422 bp StuI-Styl fragment from the plasmid pKPN15 (constructed as described above in Example 20), was cloned into the StuI-Styl sites of pBS5, creating the plasmid pBS5MASE. pBS5MASE was then mutagenized to introduce therein a PacI site between the

transcription promoter and the translation initiation site, with the following synthetic oligonucleotide which was constructed extemporaneously :

SEQ ID NO:11

5' -ATTATATTATCCTTCTATTTAATTAATCTGAATAAGAGGAG-3'

PacI

This mutagenesis generated plasmid pBS7MASE, which contained a supplementary PacI site in comparison with pBS5MASE.

3. Preparation of pLI7NC

The plasmid pLI7NC was thereafter constructed by replacing the 422 bp *Stu*I-*Sty*I fragment of the plasmid pLI2NC, as was described above, with the 421 bp *Sty*I-*Stu*I fragment of pBS7MASE, described above.

4. Preparation of pL7SBT

Two synthetic oligonucleotides were constructed having the following sequences :

SEQ ID NO:12

5' -CGCTTAATTAATAAATGAGGAGGGAACCGAGTGAGAAGCAAAAAATTGTGGATCAGCTT-3'

PacI

SEQ ID NO:13

5' -GATCATGGAACGAGCTCAACATGCGGAGAAAGAAGAG-3'

SacI

These oligonucleotides were then utilized for effectuating an amplification by PCR starting from the plasmid pSBT2 (obtained as described above in Example 19).

pSBT2 contains the complete gene that codes for the alkaline protease (subtilisin) of *B. subtilis* 168. The fragment amplified by PCR contained the ribosome binding site, the alkaline protease coding sequence, as well as the transcription terminator of the gene, flanked (between) by two restriction sites : PacI and SacI. The PCR was performed according to the procedure described above.

The amplified fragment was purified on agarose gel (1 % w/v), digested by PacI and SacI and cloned into the SacI-PacI sites of the pLI7NC vector, generating the plasmid pLI7SBT.

A derivative of plasmid pLI7SBT able to replicate in *B. subtilis* and *B. licheniformis* was then constructed by replacing the replication functions for *E. coli*, carried by the 4.8 kbp SacI-BglII fragment of the plasmid pLI7SBT with the 2199 bp BglII-SacI fragment isolated from plasmid pUB131 which includes the fragment carrying the replication functions for *Bacillus*.

Replacement of the replication functions was done by subcloning, in *B. subtilis* SE3, the 3318 bp BglII-SacI fragment from plasmid pLI7SBT into the 2199 bp BglII-SacI fragment isolated from plasmid pUB131. The resulting plasmid is the plasmid pL7SBT (figure 8).

Example 22

Preparation of Alpha-Amylase Expression Vector pL7TAKA

Expression vector pL7TAKA (figure 9) contains the sequence coding for the α -amylase of *B. licheniformis* ATCC 9789 under control of the transcription promoter of the alkaline protease of *B. licheniformis* SE2. This plasmid (pL7TAKA) was obtained as described below.

First, plasmid pS, which contains the complete α -amylase gene of *B. licheniformis* ATCC 9789 cloned on a 3.5 kbp *Eco*RI fragment in the *Eco*RI site of pUB110, was isolated. The isolation was carried out as follows :

The chromosomal DNA from *B. licheniformis* ATCC 9789, was extracted and purified from a 200 ml L-B culture. The chromosomal DNA preparation was then partially digested with EcoRI. The DNA fragments obtained were then ligated to the vector pUB110, which had previously been linearized by EcoRI. The resulting ligation mixture was transformed into *B. subtilis* BR151, using the protoplast method. The regenerated transformants were then transferred to L-B medium supplemented with 25 µg/ml kanamycin and 1 % (w/v) starch.

After 18 hours of growth at 37 °C, the transformant colonies were covered with a 0.0025 % iodine solution. A colony was then identified which showed a larger starch hydrolysis halo than the control strain (*B. subtilis* BR151) carrying the plasmid pUB110. The plasmid pS was extracted from this transformant, isolated, and analysed by restriction mapping. Plasmid pS contained an approximately 3.5 kbp inserted DNA fragment from *B. licheniformis* ATCC 9789. The sequences of the inserted fragment was determined using the same approach as for the xylanase gene described above in Example 17.

Two synthetic oligonucleotides were constructed having the following sequences :

SEQ ID NO:14

5'-CTTGTTAAAAATTCGGAATATTTAATTAAATCATATGTTTCA-3'

PacI

SEQ ID NO:15

5'-GCTGCAAAGCATAATGATGACGGTCC-3'

These two synthetic oligonucleotides were then utilized for effectuating an amplification by PCR starting from plasmid pS.

The fragment amplified by PCR contains the ribosome binding site and the sequence coding for the α-amylase of *B. licheniformis* ATCC 9789, as well as the transcription terminator of the gene, flanked (between) two restriction sites PacI and SacI.

Plasmid pLI7NC was then prepared as described above in Example 21.

The amplified fragment was purified on agarose gel (1 %), digested by PacI and SacI and then cloned into the SacI-PacI sites of the vector pLI7NC, generating the plasmid pLI7TAKA.

A derivative of plasmid pLI7TAKA that was able to replicate in *B. subtilis* and *B. licheniformis* was then constructed by replacing the replication functions for *E. coli* carried by the 3623 bp BgIII-BgIII fragment of the plasmid pLI7TAKA with the 2238 bp BgIII-BamHI fragment isolated from plasmid pUB131, which includes the fragment carrying the replication functions for *Bacillus*.

Replacement of replication functions was carried out by cloning, in *B. subtilis* SE3, the 5.1 kbp BgIII-BgIII fragment of plasmid pLI7TAKA into the 2238 bp BgIII-BamHI fragment isolated from plasmid pUB131. The resulting plasmid is pL7TAKA (figure 9).

Example 23

Cloning of The Terminal Portions of the Alkaline Protease Gene of the *Bacillus licheniformis* Host Strain

In order to isolate the alkaline protease gene from the chromosomal DNA of *B. licheniformis* SE2, the strategy used was to, first, extract the chromosomal DNA. Then, the terminal portions of this gene were cloned by hybridization with oligonucleotide probes.

1. Extraction Of Chromosomal DNA from *B. licheniformis* SE2

The chromosomal DNA from *Bacillus licheniformis* SE2 was extracted and purified as described above in the section headed "Methods and Techniques".

2. Cloning of the C-Terminal Portion of the Alkaline Protease Gene

The preparation of extracted chromosomal DNA was then submitted to a restriction analysis. The DNA fragments resulting from these digestions were then separated according to size on a 0.8 % (w/v) agarose gel.

The agarose gel was then submitted to an analysis by the Southern Blot Technique, so as to identify the restriction fragments which contain the nucleotide sequences of the C-terminal part of the alkaline protease gene.

The probe constructed and used for the hybridizations was a synthetic oligonucleotide corresponding to the C-terminal part of the alkaline protease gene. The synthetic oligonucleotide sequence that was constructed for this purpose was :

SEQ ID NO: 16

5' - GGCGGAGCAAGCTTTGTGG - 3' for the C-Terminal

The results showed that the C-terminal portion of the alkaline protease gene was localized on a PstI fragment of about 2.7 kbp.

The preparation of extracted chromosomal DNA from *B. licheniformis* SE2 was then digested with PstI and separated according to size by agarose gel electrophoresis (0.8 %). The resulting obtained fragments of about 2.7 kbp were then extracted from the gels and purified following the Gene Clean procedure. The 2.7 kbp PstI fragments were then ligated with the plasmid pUC18, which had been previously digested at the PstI site and dephosphorylated. The ligation thus obtained was then transformed into cells of *Escherchia coli* MC1061 by the CaCl₂ technique.

The transformants were selected on a L-B plate medium supplemented with 100 µg/ml ampicillin. The transformants obtained in the *E. coli* MC1061 were then screened by hybridization with the radiolabeled synthetic oligonucleotide used as the C-terminal probe in the Southern study and the plasmid pKC1 isolated thereby.

3. Cloning of the N-Terminal Portion of the Alkaline Protease Gene

The preparation of extracted chromosomal DNA was then submitted to a restriction analysis. The DNA fragments resulting from these digestions were then separated according to size on a 0.8 % agarose gel.

The agarose gel was then submitted to an analysis by the Southern Blot Technique, so as to identify the restriction fragments which contain the nucleotide sequences of the N-terminal part of the alkaline protease gene.

The probe constructed and used for the hybridizations was a synthetic oligonucleotide corresponding to the N-terminal part of the alkaline protease gene. The synthetic oligonucleotide sequence that was constructed for this purpose was :

SEQ ID NO: 17

5'- ATGGCTCCTGGCGCAGGC -3' for the N-Terminal

The results show that the N-terminal portion of the alkaline protease gene was localized on a PstI fragment of about 5.5 kbp, and equally on a smaller BclI-PstI fragment of about 2 kbp. This fragment did not contain restriction sites for XbaI, ClaI, HpaI and SphI.

The preparation of extracted chromosomal DNA from *B. licheniformis* SE2 was then digested with PstI and then separated according to size by agarose gel electrophoresis (0.8 %). The resulting obtained fragments of about 5.5 kbp were then extracted from the gels and purified following the Gene Clean procedure. The resulting 5.5 kbp PstI fragments were then submitted to a series of digestions with BclI, XbaI, ClaI, HpaI and SphI. The DNA fragments thus generated were ligated with plasmid pMK4 (as described in Sullivan, et al., (1984), Gene 29:21-26) which had been previously linearized by BamHI and PstI.

The ligations thereby obtained were then transformed into cells of *E. coli* MC1061 by the CaCl₂ technique.

The transformants were selected on a L-B plate medium supplemented with 100 µg/ml ampicillin. The transformants obtained in the *E. coli* MC1061 were then screened by hybridization with the radiolabeled synthetic oligonucleotide used as the N-terminal probe in the Southern study and the plasmid pKP1 isolated thereby.

Example 24

Sequencing of the Alkaline Protease Gene

The fragments inserted in the plasmids pKP1 and pKC1 were sequenced from the PstI to the SacI sites thereof by the procedure described above in "Methods and Techniques", using the strategy of progressive oligonucleotides.

Construction of pLD1 Deletion Plasmid of Mature Alkaline Protease

The DNA fragment present on pKC1 and located downstream from the N-terminal of the alkaline protease sequence was thereafter isolated on a 1.2 kbp SacI-HindIII fragment of pKC1 (constructed as described above in Example 23, part 2). This isolation was carried out by, first, digestion of pKC1 with HindIII. The HindIII 5' protruding end was then made blunt by treatment with Klenow fragment of DNA polymerase. A SacI restriction was then performed, so as to generate the desired SacI-HindIII (blunt) fragment. This fragment was then cloned into the SacI and HpaI sites of pKPN14, thereby generating the plasmid pLID1.

All of the above constructions were effectuated by transformation of the strain *E. coli* MC1061 and in the presence of tetracycline (12 µg/ml) for the selection of transformants.

A derivative of the plasmid pLID1 that was able to replicate in strains of *B. subtilis* and *B. licheniformis* was thereafter constructed by replacing the functions of replication for *E. coli*, carried by the 3623 bp BgIII-BgIII fragment of the pLID1 plasmid with the fragment carrying the replication functions for *Bacillus*: a 2238 bp BgIII-BamHI fragment isolated from plasmid pUB131.

Replacement of the functions of replication for *E. coli* with those for *Bacillus* was done by first isolating the 3.6 kbp BgIII-BgIII fragment from the pLID1 plasmid (the fragment carrying the 5' upstream sequence and the 3' downstream sequence of the alkaline protease gene of *B. licheniformis* SE2) by digesting pLID1 with BgIII and BamHI. The additional BamHI digestion was necessary, since a BgIII digestion alone would have resulted in fragments with identical sizes which would not have been able to be separated as desired by agarose gel electrophoresis. The 3.6 kbp BgIII-BgIII fragment was then cloned in *B. subtilis* SE3, into the 2238 bp BgIII-BamHI fragment which was isolated from plasmid pUB131, generating plasmid pLD1 (figure 11).

Example 26

Construction of pLD3 Deletion Plasmid of the Sequence Coding for the Entire Alkaline Protease

A further deletion plasmid, pLD3 (Figure 12), was constructed for the purpose of preparing *B. licheniformis* SE2 delap3. This plasmid pLD3 was obtained as described below.

A double-stranded synthetic oligonucleotide having the sequence :

```

SEQ ID NO:22  5'-CCT TTAATTAA CCTTGG CGGCCG CTCGAG GAGCT-3'
SEQ ID NO:23  3'-GGA AATTAATT GGAACC GCCGGC GAGCTC C   -5'
              (StuI)  PacI   StyI   NotI   XhoI  (SacI)

```

was constructed. This synthetic oligonucleotide was then cloned into the SacI and StuI sites of the plasmid pLID1 (constructed as described above in Example 25) generating the plasmid pLD3.

A derivative of plasmid pLD3 that was able to replicate in strains of *Bacillus* was thereafter constructed by replacing the replication functions for *E. coli*, carried by the 3623 bp BgIII-BgIII fragment of the plasmid pLD3 with the 2238 bp BgIII-BamHI fragment (the fragment carrying the replication functions for *Bacillus*) isolated from plasmid pUB131.

Replacement of the functions of replication for *E. coli* with those for *Bacillus* was done by cloning the 3.2 kbp BgIII-BgIII fragment of the plasmid pLD3 into the 2238 bp BgIII-BamHI fragment isolated from pUB131. The resulting plasmid is the plasmid pLD3 (figure 12).

Example 27

Construction of pLD6 Deletion Plasmid of the Sequence Coding for the Entire Alkaline Protease Gene, Including the Transcription Promoter.

A still further deletion plasmid, pLD6 (Figure 13), was constructed for the purpose of preparing *B. licheniformis* SE2 delap6. This deletion plasmid, pLD6, was obtained as described below.

The plasmid pLD6 was constructed by deleting the 0.9 kbp AflIII-AflIII fragment of the plasmid pLD3 (constructed as described above in Example 26). A derivative of this plasmid that was able to replicate in strains of *Bacillus* was then constructed by replacing the replication functions of *E. coli* that are carried by the 3623 bp BgIII-BgIII fragment of the plasmid pLD6 with the 2238 bp BgIII-BamHI fragment (the fragment carrying the replication functions for *Bacillus*) isolated from pUB131.

EP 0 634 490 A1

Replacement of the functions of replication for *E. coli* with those for *Bacillus* was done by cloning the 2.3 kbp BgIII-BgIII fragment from plasmid pLD6 (the fragment carrying the 5' upstream sequence and the 3'downstream sequence of the alkaline protease gene of *B. licheniformis* SE2) into the 2238 bp BgIII-BamHI fragment isolated from plasmid pUB131. The result is plasmid pLD6 (figure 13).

5

Example 28

Creation, in vivo, of Deleted *B. licheniformis* strains

10 The desired deletions in the chromosomal DNA of *Bacillus licheniformis* SE2 were performed using techniques that are based on homologous recombination, as shall be discussed at length below. The results of the chromosomal deletions obtained, respectively, by the plasmids pLD1, pLD3 and pLD6 are represented in figure 10. The deletions were effectuated, as described below, to produce *B. licheniformis* strains SE2 delap1, SE2 delap3 and SE2 delap6.

15 Each of the deletion plasmids (pLD1, pLD3 or pLD6) were transformed into the respective *Bacillus licheniformis* SE2 delap cultures by the protoplast technique.

Respective transformants were isolated from each of the transformations and the restriction maps of the deletion plasmid introduced therein were verified.

20 The transformants were thereafter placed in respective cultures of 50 ml of L-B medium supplemented by 2 g/l of glucose and 25 µg/ml of kanamycin, for 18 hours at 37 °C.

A volume of 0.1 ml of each of the respective resulting cultures were inoculated into respective flasks containing 50 ml of the same medium, and the cultures were carried out for 18 hours at 37 °C. A sample of each of the resulting cultures was withdrawn, and appropriate dilutions were plated on respective protease detection plates supplemented with 25 µg/ml of kanamycin.

25 The respective plates were visually screened for the presence of colonies showing the absence of zoning, indicating the inability of these colonies to produce alkaline protease. The culturing and screening operations were repeated until respective deleted candidates, which were both unable to produce alkaline protease (*apr*⁻) and which were resistant to kanamycin (*Km*^r) due to the presence of the respective deletion plasmids, were isolated (*apr*⁻, *Km*^r).

30 The plasmids having served for the deletions were thereafter eliminated from the deleted candidate *B. licheniformis* strain (strain SE2 delap1, SE2 delap3, or SE2 delap6) which they had transformed by simple growth on culture media at 37 °C in the absence of an antibiotic.

35 The deleted candidates were thereafter placed in respective cultures of 50 ml of L-B medium supplemented by 2 g/l of glucose for 18 hours at 37 °C. Volumes of 0.1 ml of the resulting cultures were inoculated into respective second flasks, each containing 50 ml of the same medium, and the respective cultures were carried out for 18 hours at 37 °C. A sample of the resulting cultures were withdrawn, and appropriate dilutions were plated on L-B plates. The isolated colonies were then replicated on respective second L-B plates supplemented with 25 µg/ml kanamycin, and visually inspected to identify kanamycin sensitive (*Km*^s) colonies.

40 The culturing and screening operations were repeated for each colony until *Km*^s candidates were isolated. These candidate strains were then isolated and their phenotypes (*apr*⁻, *Km*^s) were confirmed.

45 The chromosomal DNA was thereafter isolated and purified, and the structure of the chromosomal deletion was verified by the Southern blotting technique. The deletions were found to be well-positioned, having taken place by means of the double homologous recombination into the sequences situated upstream (5') and downstream (3'), as is seen in figure 10. In figure 10, the dotted lines indicate the absence of the deleted sequence(s) in the *B. licheniformis* SE2 chromosomal DNA.

The resulting strain(s) were designated, respectively, *B. licheniformis* SE2 delap1, SE2 delap3 and SE2 delap6, respectively. None of these strains produced alkaline protease.

50 Example 29

Transformation of Deleted *B. licheniformis* SE2 Strains With pUB-BPX12

55 pUB-BPX12 (figure 4) was extracted from *E. coli* MC1061 obtained in Example 17 and isolated and purified. Each of the deleted *B. licheniformis* SE2 strains (delap1, delap3 and delap6), obtained as described above in Example 28, was then transformed by respective pUB-BPX12 plasmids, following the protoplast technique and respective transformants were selected, isolated and purified.

The resulting transformed strains were *B. licheniformis* SE2 delap1 (pUB-BPX12); delap3 (pUB-BPX12); and delap6 (pUB-BPX12). The transformants were then placed in respective cultures, as will be described below in Example 33, to produce the xylanase of the present invention. The presence of this plasmid confers to the resulting recombinant deleted *B. licheniformis* SE2 strains the following properties : 1. Extracellular production of xylanase; and 2. Kanamycin or phleomycin resistance.

Example 30

Transformation of Deleted *B. licheniformis* SE2 Strains With Other Expression Vectors

pUBDEBRA1 (Figure 5) obtained as was described above in Example 18, pKAC1 (Figure 6) obtained as was described above in Example 19, pL11 (Figure 7) obtained as was described above in Example 20, pL7SBT (Figure 8) obtained as was described above in Example 21, and pL7TAKA (Figure 9) obtained as was described above in Example 22 were all extracted from their respective hosts and isolated and purified. Five cultures of each of the deleted *B. licheniformis* SE2 strains (delap1, delap3 and delap6) were obtained, as described above in Examples 28. A respective culture of each of these deleted strains was then transformed by one of the respective plasmids. Transformations were performed using the protoplast technique.

Transformants in each of these five respective cultures were then selected, isolated and purified.

The transformants were then placed in further respective cultures as will be described below in Example 34 to produce the respective enzyme that is coded for thereby.

Example 31

Transformation of *B. subtilis* SE3 With Expression Vectors

pUB-BPX12 (figure 4) obtained as was described above in Example 17, pUBDEBRA1 (Figure 5) obtained as was described above in Example 18, pKAC1 (Figure 6) obtained as was described above in Example 19, pL11 (Figure 7) obtained as was described above in Example 20, pL7SBT (Figure 8) obtained as was described above in Example 21, and pL7TAKA (Figure 9) obtained as was described above in Example 22 were all extracted from their respective hosts and isolated and purified. Six (6) cultures of *Bacillus subtilis* SE3 were prepared. Each of the cultures was then transformed by one of the respective plasmids. Transformations were performed using the protoplast technique.

Transformants in each of these five respective cultures were then selected, isolated and purified.

The transformants were then placed in further respective cultures as will be described below in Example 35 to produce the respective enzyme that is coded for thereby.

Example 32

Transformation of *B. pumilus* PRL B12 With pUB-BPX12

pUB-BPX12 (figure 4) was extracted from the *E. coli* MC1061 obtained in Example 17 and isolated and purified. pUB-BPX12 was then introduced by transformation in the strain *B. pumilus* PRL B12 by the protoplast method. The transformants were directly selected on DM3 media in the presence of phleomycin at 20 µg/ml.

Transformants in each of these five respective cultures were then selected, isolated and purified.

The transformants were then placed in further respective cultures as will be described below in Example 36 to produce the xylanase of the present invention.

Example 33

Expression of pUB-BPX12 in Deleted *B. licheniformis* SE2 Strains

Respective cultures of the deleted *B. licheniformis* SE2 strains (delap1, delap3 and delap6), that were transformed with the expression vector pUB-BPX12 as described above in Example 29, were obtained.

The transformants were cultivated for 17 hours at 37 °C in a preculture of L-B medium supplemented with 0.5 % glucose (w/v), and 20 µg/ml (w/v) kanamycine. This preculture was inoculated (5 % v/v) into 50 ml of M2 medium (described in example 1), supplemented with 20 µg/ml kanamycin, in baffled erlenmeyer

flasks. The cultures were carried out under agitation during 80 hours at 37 °C. After 80 hours of culture in the conditions described, the cellular biomass was eliminated by centrifugation at 5000 RPM for 10 minutes.

The enzymatic activity of the xylanase in the culture broths was then determined and the quantity of protein (μ grams) was then calculated in function of specific activity of the enzyme. These results were then compared to the enzymatic activity of the host strain *B. licheniformis* SE2 delap1, transformed by the pUB131 control plasmid (see Table 10 below).

The results obtained are presented below in Table 10 and are given in percentages by comparison to the quantity of alkaline protease produced by the deleted *B. licheniformis* SE2 strain containing the plasmid pLI1 (Figure 7), which contains an alkaline protease Carlsberg gene.

Example 34

Expression by Expression Vectors in Deleted *B. licheniformis* SE2 Strains

Respective cultures of the deleted *B. licheniformis* SE2 strains (delap1, delap3 and delap6), that were transformed with the expression vectors pUBDEBRA1, pKAC1, pLI1, pL7SBT and pL7TAKA, as described above in Example 30, were obtained.

The transformants were cultivated for 17 hours at 37 °C in a preculture of L-B medium supplemented with 0.5 % glucose (w/v), and 20 μ g/ml (w/v) kanamycine. This preculture was inoculated (5 % v/v) into 50 ml of M2 medium (described in example 1), supplemented with 20 μ g/ml kanamycin, in baffled erlenmeyer flasks. The cultures were carried out under agitation during 80 hours at 37 °C. After 80 hours of culture in the conditions described, the cellular biomass was eliminated by centrifugation at 5000 RPM for 10 minutes.

The enzymatic activity of the pullulanase, α -amylase and alkaline proteases in the culture broths were then determined and the quantity of protein (μ grams) was then calculated in function of specific activity of the enzyme. These results were then compared to the enzymatic activity of the host strain *B. licheniformis* SE2 delap1, transformed by the pUB131 control plasmid (see Table 10 below).

The results obtained are presented below in Table 10 and are given in percentages by comparison to the quantity of alkaline protease produced by the deleted *B. licheniformis* SE2 strain containing the plasmid pLI1 (Figure 7), which contains an alkaline protease Carlsberg gene.

Example 35

Expression by Expression Vectors in *B. subtilis* SE3

Respective cultures of *B. subtilis* SE3 that were transformed with the expression vectors pUB-BPX12, pUBDEBRA1, pKAC1, pLI1, pL7SBT, and pL7TAKA, as described above in Example 31, were obtained.

The transformants were cultivated for 17 hours at 37 °C in a preculture of L-B medium supplemented with 0.5 % glucose (w/v), and 20 μ g/ml (w/v) kanamycine. This preculture was inoculated (5 % v/v) into 50 ml of M3 medium (described in example 1), supplemented with 20 μ g/ml kanamycin, in baffled erlenmeyer flasks. The cultures were carried out under agitation during 80 hours at 37 °C. After 80 hours of culture in the conditions described, the cellular biomass was eliminated by centrifugation at 5000 RPM for 10 minutes.

The enzymatic activity of the xylanase, pullulanase, α -amylase and alkaline proteases in the culture broths were then determined and the quantity of protein (μ grams) was then calculated in function of specific activity of the enzyme. These results were then compared to the enzymatic activity of the host strain *B. licheniformis* SE2 delap1, transformed by the pUB131 control plasmid (see Table 10 below).

The results obtained are presented below in Table 10 and are given in percentages by comparison to the quantity of alkaline protease produced by the deleted *B. licheniformis* SE2 delap1 strain containing the plasmid pLI1 (Figure 7), which contains an alkaline protease Carlsberg gene.

Example 36

Expression by Expression Vector pUB-BPX12 In *B. pumilus* PRL B12

A culture of the *B. pumilus* PRL B12 strain, that was transformed with the expression vector pUB-BPX12, as described above in Example 32, was obtained.

The transformants were directly selected on DM3 media in the presence of phleomycine at 20 μ g/ml.

A transformant colony was then cultivated for 24 hours at 37 °C in the preculture medium described above in example 1, supplemented with 25 μ g/ml (w/v) kanamycine. This preculture was inoculated (5 %

v/v) into 50 ml of M1 medium (described in example 1), supplemented with 20 µg/ml kanamycin, in a baffled erlenmeyer flask, conforming to the protocol described above in Example 1. The culture was carried out under agitation during 40 hours at 30 °C.

After 40 hours of culturing, the extracellular mixture of the culture broth containing the xylanase of *B. pumilus* PRL B12 was separated from the cellular biomass by centrifugation at 5000 rpm for 10 minutes.

The enzymatic activity of the xylanase in the culture broth was then determined and the quantity of protein (µ grams) was then calculated in function of specific activity of the enzyme. These results were then compared to the enzymatic activity of the host strain *B. licheniformis* SE2 delap1, transformed by the pUB131 control plasmid (see Table 10 below).

The results obtained are presented below in Table 10 and are given in percentages by comparison to the quantity of alkaline protease produced by the deleted *B. licheniformis* SE2 delap1 strain containing the plasmid pLI1 (Figure 7), which contains an alkaline protease Carlsberg gene.

Example 37

Yields of the Various Enzymes Produced From Various Hosts

The various supernatants described above in Examples 33, 34, 35 and 36, were analyzed for the protein content of the respective enzymes secreted from the three *Bacillus* hosts tested. Results are presented below in table 10. In Table 10 :

- (1) stands for *B. licheniformis* SE2 delap1;
- (2) stands for *B. licheniformis* SE2 delap3;
- (3) stands for *B. licheniformis* SE2 delap6;
- (4) stands for *B. subtilis* SE3; and
- (5) stands for *B. pumilus* PRL B12.

In table 10, the numbers indicated in the table correspond to the quantity of the respective enzymes (mg protein/ml) secreted by the relevant host strains (mg of enzyme/ml of culture supernatant), expressed as percentages of the quantity of homologous alkaline protease Carlsberg secreted by *B. licheniformis* SE2 delap1, from plasmid pLI1.

The amount of protein corresponding to each enzyme is measured as described in the experimental part under the heading "Methods and Techniques".

"NS" indicates that the plasmids were highly unstable in the corresponding host strains, and productivity data are therefore not available.

TABLE 10

Productivity (%) of Expression Vectors in <i>B. licheniformis</i> SE2 delap strains						
Plasmid	Expressed gene	Host Strain Relative Yield				
		(1)	(2)	(3)	(4)	(5)
pLI1	(subtilisin Carlsberg)	100	---	---	NS	---
pUB-BPX12	(xylanase)	215	---	220	9	47
pUBDEBRA1	(pullulanase)	95	---	---	NS	---
pKAC1	(subtilisin 168)	35	---	101	<5	---
pL7SBT	(subtilisin 168)	50	---	133	NS	---
pL7TAKA	(α-amylase)	10	---	32	NS	---

The results show that the deleted *B. licheniformis* strains are a much more advantageous host than *B. subtilis*, in that secretion of heterologous proteins is much more efficient. For example, *B. licheniformis* SE2 delap6 (pUB-BPX12) is able to produce 24 times more xylanase than *B. subtilis* SE3 (pUB-BPX12), under the same conditions, and using the same expression vector (pUB-BPX12). The yields obtained with expression vector pUB-BPX12 in this *B. licheniformis* SE2 delap6 host are even 4.8-fold higher than the yields obtained with the same expression vector in the strictly homologous expression host *B. pumilus* PRL B12.

Moreover, several expression vectors were found to be totally unstable in *B. subtilis* SE3 : pLI1 (Carlsberg protease), pL7TAKA (α-amylase), pL7SBT (subtilisin 168), and pUBDEBRA1 (pullulanase). In all these cases, transformants could hardly been obtained, since deletions in the expression vectors occurred

at a high frequency. On the other hand, in the *B. licheniformis* SE2 delap1 and delap6 strains, the same expression vectors were found to be very stable, and good yields were obtained.

Some heterologous enzymes, for example xylanase (220 %), and to a lesser extent, subtilisin 168 (133 %) were produced in even larger quantities than the homologous Carlsberg protease used as a reference in this experiment.

Some enzymes are produced at a similar yield to the homologous protease Carlsberg used as reference in this experiment (for example, pullulanase (105 %)).

Table 10 also demonstrates the better efficiency of the homologous transcription promoter from *B. licheniformis*, to drive the synthesis of subtilisin 168. Comparing the results for the expression of the pL7SBT to those seen for the pKAC1 plasmid, it can be seen that the productivity is indeed 31 % higher using the homologous alkaline protease transcription promoter than the heterologous *B. subtilis* promoter.

Thus, the results of Table 10 clearly show that the deleted *B. licheniformis* SE2 strains, as described herein, are excellent hosts for the heterologous expression of proteins.

Obviously many modifications may be made without departing from the basic spirit of the invention. Accordingly, it will be appreciated by those skilled in the art that within the scope of the appended claims, the invention may be practiced other than has been specifically described herein.

BIBLIOGRAPHY

- (1) Simpson, F., Microbial Pentosanases II. Some Factors Affecting the Production of Pentosanases by *Bacillus pumilus* and *Bacillus subtilis*, Can. J. Microbiol., 2:28-38 (1956).
- (2) German Patent Application, Serial Number DE 4023458.
- (3) Molecular Cloning -- Laboratory Manual, (Sambrook, Fritsch, Maniatis) 2nd edition (1989).
- (4) Molecular Biological Methods for *Bacillus* (Harwood, C. R., and Cutting, S. M., eds) John Wiley and Sons (1990).
- (5) DNA Cloning, Volume II, Editor : Glover, D. M., IRL press, Oxford, (1985)
- (6) Molecular Cloning, A Laboratory Manual. (Maniatis, T., Fritsch, E. F., and Samrook, J) Cold Spring Harbor Laboratory (1982).

LIST OF ABBREVIATIONS USED IN DRAWINGS

The following is a list of the abbreviations which have been utilized (throughout the application) in the drawings :

REP	Replication Initiation Protein
ORI +	Origin of Plus Strand Synthesis
ORI-	Minus Origin of Replication
KMR	Gene Conferring Resistance to Kanamycin
BLMR	Gene Conferring Resistance to Bleomycin
MAT	Mature Protein
PRE	Pre-Sequence
PP	Pre-Pro Sequence
BPXYL	Sequence Coding for <i>B. pumilus</i> PRL B12 xylanase
BSUAPR	Sequence Coding for <i>B. subtilis</i> subtilisin
BLIAMY	Sequence Coding for <i>B. licheniformis</i> alpha-amylase
BLIAPR	Sequence Coding for <i>B. licheniformis</i> alkaline protease
5'BLIAPR	5' Upstream Sequence of BLIAPR
3'BLIAPR	3' Downstream Sequence of BLIAPR

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- 5 (i) APPLICANT:
 (A) NAME: SOLVAY (Société Anonyme)
 (B) STREET: Rue du Prince Albert, 33
 (C) CITY: Bruxelles
 (E) COUNTRY: Belgique
 10 (F) POSTAL CODE (ZIP): 1050
 (G) TELEPHONE: 02/509 61 11
- (ii) TITLE OF INVENTION: XYLANASE DERIVED FROM A BACILLUS SPECIES,
 EXPRESSION VECTORS FOR SUCH XYLANASE AND OTHER PROTEINS, HOST
 ORGANISMS THEREFOR AND USE THEREOF.
- 15 (iii) NUMBER OF SEQUENCES: 35
- (iv) COMPUTER READABLE FORM:
 (A) MEDIUM TYPE: Floppy disk
 (B) COMPUTER: IBM PC compatible
 20 (C) OPERATING SYSTEM: PC-DOS/MS-DOS

(2) INFORMATION FOR SEQ ID NO: 1:

- 25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1022 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: genomic DNA
- 30 (vi) ORIGINAL SOURCE:
 (A) ORGANISM: Bacillus pumilus
 (B) STRAIN: PRL B12

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

35 TCATGTAAC TCGCTTGATC TATTTCA TTT GTATCAAAGG ATTTATACAC AAACAAGAGA 60
 CATCCATGCC GGGTTAAAGC AGTATCGTTC CATCTAACAG AGAAGGNC TG CATGAAAGGA 120
 GGTGATGGGT TTTTCATCTT AGGGATGACA GAACAATACG GATGAAAAA GGAGAGGGAT 180
 GGAAA ATG AAT TTG AAA AGA TTG AGG CTG TTG TTT GTG ATG TGT ATT GGA 230
 40 Met Asn Leu Lys Arg Leu Arg Leu Leu Phe Val Met Cys Ile Gly
 -25 -20 -15

TTT GTG CTG ACA CTG ACG GCT GTG CCG GCT CAT GCG GAA ACG ATT TAT 278
 Phe Val Leu Thr Leu Thr Ala Val Pro Ala His Ala Glu Thr Ile Tyr
 -10 -5 1

45 GAT AAT AGG ATA GGG ACA CAC AGC GGA TAC GAT TTT GAA TTA TGG AAG 326
 Asp Asn Arg Ile Gly Thr His Ser Gly Tyr Asp Phe Glu Leu Trp Lys
 5 10 15 20

GAT TAC GGA AAT ACC TCG ATG ACA CTC AAT AAC GGC GGG GCA TTT AGT 374
 50 Asp Tyr Gly Asn Thr Ser Met Thr Leu Asn Asn Gly Gly Ala Phe Ser
 25 30 35

EP 0 634 490 A1

	GCA AGC TGG AAC AAT ATT GGA AAT GCC TTA TTT CGA AAA GGA AAG AAG	422
	Ala Ser Trp Asn Asn Ile Gly Asn Ala Leu Phe Arg Lys Gly Lys Lys	
	40 45 50	
5	TTT GAT TCC ACT AAA ACT CAT CAT CAA CTT GGC AAC ATC TCC ATC AAC	470
	Phe Asp Ser Thr Lys Thr His His Gln Leu Gly Asn Ile Ser Ile Asn	
	55 60 65	
	TAC AAC GCA GCC TTT AAC CCG GGC GGG AAT TCC TAT TTA TGT GTC TAT	518
	Tyr Asn Ala Ala Phe Asn Pro Gly Gly Asn Ser Tyr Leu Cys Val Tyr	
	70 75 80	
10	GGC TGG ACA CAA TCT CCA TTA GCT GAA TAC TAC ATT GTT GAG TCA TGG	566
	Gly Trp Thr Gln Ser Pro Leu Ala Glu Tyr Tyr Ile Val Glu Ser Trp	
	85 90 95 100	
	GGC ACA TAT CGT CCA ACA GGA ACG TAT AAA GGA TCA TTT TAT GCC GAT	614
	Gly Thr Tyr Arg Pro Thr Gly Thr Tyr Lys Gly Ser Phe Tyr Ala Asp	
	105 110 115	
	GGA GGC ACA TAT GAC ATA TAT GAA ACG CTC CGT GTC AAT CAG CCT TCT	662
	Gly Gly Thr Tyr Asp Ile Tyr Glu Thr Leu Arg Val Asn Gln Pro Ser	
	120 125 130	
20	ATC ATT GGA GAC GCT ACC TTC AAA CAA TAT TGG AGT GTA CGT CAA ACA	710
	Ile Ile Gly Asp Ala Thr Phe Lys Gln Tyr Trp Ser Val Arg Gln Thr	
	135 140 145	
	AAA CGC ACA AGC GGA ACG GTC TCC GTC AGT GAG CAT TTT AAA AAA TGG	758
	Lys Arg Thr Ser Gly Thr Val Ser Val Ser Glu His Phe Lys Lys Trp	
	150 155 160	
	GAA AGC TTA GGC ATG CCA ATG GGA AAA ATG TAT GAA ACA GCA TTA ACT	806
	Glu Ser Leu Gly Met Pro Met Gly Lys Met Tyr Glu Thr Ala Leu Thr	
	165 170 175 180	
30	GTA GAA GGC TAC CGA AGC AAC GGA AGT GCG AAT GTC ATG ACG AAT CAG	854
	Val Glu Gly Tyr Arg Ser Asn Gly Ser Ala Asn Val Met Thr Asn Gln	
	185 190 195	
	CTG ATG ATT CGA TAAAAGCATA TGAAAAAAGC CAGCAAAAAA TGGCTGGCTT	906
	Leu Met Ile Arg	
	200	
35	TTTTCTATGA TAATTTTCA ACTTCCACTC TGCCAGAAAA GAACGTCGCG CCGCCTCCCA	966
	TATCTGCCAA TCGATCAGGT GTTAACCCAT TCACTAAATG CTTTTGCTCT TTTTGA	1022

- 40 (2) INFORMATION FOR SEQ ID NO: 2:
- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE : Peptide
 - (v) FRAGMENT TYPE: N-terminal
 - (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Bacillus pumilus
 - (B) STRAIN: PRL B12

55

EP 0 634 490 A1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Glu Thr Ile Tyr Asp Asn Arg Ile Gly Thr His Ser Gly Tyr Asp
1 5 10 15

5

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

10

(ii) MOLECULE TYPE: nucleic acid (synthetic oligonucleotide)

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

GTAGAGGATC ATCATGT

17

20

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

25

(ii) MOLECULE TYPE: nucleic acid (synthetic oligonucleotide)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

30

TACCTTGTCT ACAAACCCC

19

35

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

40

(ii) MOLECULE TYPE: nucleic acid (synthetic oligonucleotide)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

TGAGTTGCTA GTAACATCTC ACCGA

25

45

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

50

55

EP 0 634 490 A1

(ii) MOLECULE TYPE: nucleic acid (synthetic oligonucleotide)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

AAGCTTGTAT GCCTGCAG

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: nucleic acid (synthetic oligonucleotide)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

GATCCCCTTG GCTGCAGGAG CT

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: nucleic acid (synthetic oligonucleotide)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

CCTGCAGCCA AGGG

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 52 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: nucleic acid (synthetic oligonucleotide)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

GATCCCCGGG ACCTTAGGCC TTTAATTAAC CTTGGCGGCC GCTCGAGGAG CT

(2) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 44 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

EP 0 634 490 A1

(ii) MOLECULE TYPE: nucleic acid (synthetic oligonucleotide)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

5 CCTCGAGCGG CCGCCAAGGT TAATTAAAGG CCTAAGGTCC CGGG 44

(2) INFORMATION FOR SEQ ID NO: 11:

10 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 42 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: nucleic acid (synthetic oligonucleotide)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

ATTATATTAT CTTCTATTT AATTAATCTG AATAAGAGG AG 42

20 (2) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 58 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
25 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: nucleic acid (synthetic oligonucleotide)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

30 CGCTTAATTA AAAATGAGGA GGAACCGAG TGAGAAGCAA AAAATTGTGG ATCAGCTT 58

(2) INFORMATION FOR SEQ ID NO: 13:

35 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 37 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

40 (ii) MOLECULE TYPE: nucleic acid (synthetic oligonucleotide)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

45 GATCATGGAA CGAGCTCAAC ATGCGGAGAA AGAAGAG 37

(2) INFORMATION FOR SEQ ID NO: 14:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 42 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
50 (D) TOPOLOGY: linear

55

EP 0 634 490 A1

(ii) MOLECULE TYPE: nucleic acid (synthetic oligonucleotide)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

5 CTTGTATAAAA ATTCTGAATA TTAAATTAAA TCATATGTTT CA 42

(2) INFORMATION FOR SEQ ID NO: 15:

10 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: nucleic acid (synthetic oligonucleotide)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

GCTGCAGAGC ATAATGATGA CGGTCC 26

20

(2) INFORMATION FOR SEQ ID NO: 16:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

25

(ii) MOLECULE TYPE: nucleic acid (synthetic oligonucleotide)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

30 GGCGGAGCAA GCTTTGTGG 19

(2) INFORMATION FOR SEQ ID NO: 17:

35 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

40 (ii) MOLECULE TYPE: nucleic acid (synthetic oligonucleotide)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

45 ATGGCTCCTG GCGCAGGC 18

(2) INFORMATION FOR SEQ ID NO: 18:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

50

55

EP 0 634 490 A1

(ii) MOLECULE TYPE: nucleic acid (synthetic oligonucleotide)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

5 CTTGGAGCTC GTTAACAGAT CT 22

(2) INFORMATION FOR SEQ ID NO: 19:

10 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: nucleic acid (synthetic oligonucleotide)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

CTTGAGATCT GTTAACGAGC TC 22

20 (2) INFORMATION FOR SEQ ID NO: 20:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

25 (ii) MOLECULE TYPE: nucleic acid (synthetic oligonucleotide)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

30 CATCTAATCT TCAACACCCG GGCCCGTTTG TTGAAC 36

(2) INFORMATION FOR SEQ ID NO: 21:

35 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 42 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

40 (ii) MOLECULE TYPE: nucleic acid (synthetic oligonucleotide)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

45 CAAAATAAAA AAGATACAAC CCGGGTCTCT CGTATCTTTT AT 42

(2) INFORMATION FOR SEQ ID NO: 22:

50 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

55

EP 0 634 490 A1

(ii) MOLECULE TYPE: nucleic acid (synthetic oligonucleotide)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

CCTTTAATTA ACCTTGCGG CCGCTCGAGG AGCT

34

(2) INFORMATION FOR SEQ ID NO: 23:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: nucleic acid (synthetic oligonucleotide)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

CCTCGAGCGG CCGCCAAGGT TAATTAAAGG

30

(2) INFORMATION FOR SEQ ID NO: 24:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 200 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(v) FRAGMENT TYPE : internal fragment

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Bacillus pumilus
- (B) STRAIN: PRL B12

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

Glu Thr Ile Tyr Asp Asn Arg Ile Gly Thr His Ser Gly Tyr Asp Phe
1 5 10 15

Glu Leu Trp Lys Asp Tyr Gly Asn Thr Ser Met Thr Leu Asn Asn Gly
20 25 30

Gly Ala Phe Ser Ala Ser Trp Asn Asn Ile Gly Asn Ala Leu Phe Arg
35 40 45

Lys Gly Lys Lys Phe Asp Ser Thr Lys Thr His His Gln Leu Gly Asn
50 55 60

Ile Ser Ile Asn Tyr Asn Ala Ala Phe Asn Pro Gly Gly Asn Ser Tyr
65 70 75 80

Leu Cys Val Tyr Gly Trp Thr Gln Ser Pro Leu Ala Glu Tyr Tyr Ile
85 90 95

EP 0 634 490 A1

Val Glu Ser Trp Gly Thr Tyr Arg Pro Thr Gly Thr Tyr Lys Gly Ser
100 105 110
Phe Tyr Ala Asp Gly Gly Thr Tyr Asp Ile Tyr Glu Thr Leu Arg Val
115 120 125
Asn Gln Pro Ser Ile Ile Gly Asp Ala Thr Phe Lys Gln Tyr Trp Ser
130 135 140
Val Arg Gln Thr Lys Arg Thr Ser Gly Thr Val Ser Val Ser Glu His
145 150 155 160
Phe Lys Lys Trp Glu Ser Leu Gly Met Pro Met Gly Lys Met Tyr Glu
165 170 175
Thr Ala Leu Thr Val Glu Gly Tyr Arg Ser Asn Gly Ser Ala Asn Val
180 185 190
Met Thr Asn Gln Leu Met Ile Arg
195 200

(2) INFORMATION FOR SEQ ID NO: 25:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 27 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (v) FRAGMENT TYPE : internal fragment
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Bacillus pumilus
 - (B) STRAIN: PRL B12

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

Met Asn Leu Lys Arg Leu Arg Leu Leu Phe Val Met Cys Ile Gly Phe
-25 -20 -15
Val Leu Thr Leu Thr Ala Val Pro Ala His Ala
-10 -5

(2) INFORMATION FOR SEQ ID NO: 26:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 600 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: genomic DNA

EP 0 634 490 A1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

5 GAAACGATT ATGATAATAG GATAGGGACA CACAGCGGAT ACGATTTTGA ATTATGGAAG 60
 GATTACGGAA ATACCTCGAT GACACTCAAT AACGGCGGGG CATTTAGTGC AAGCTGGAAC 120
 AATATTGGAA ATGCCTTATT TCGAAAAGGA AAGAAGTTTG ATTCCACTAA AACTCATCAT 180
 CAACTTGGCA ACATCTCCAT CAACTACAAC GCAGCCTTTA ACCCGGGCGG GAATTCCTAT 240
 TTATGTGTCT ATGGCTGGAC ACAATCTCCA TTAGCTGAAT ACTACATTGT TGAGTCATGG 300
 GGCACATATC GTCCAACAGG AACGTATAAA GGATCATTTT ATGCCGATGG AGGCACATAT 360
 GACATATATG AAACGCTCCG TGTCAATCAG CCTTCTATCA TTGGAGACGC TACCTTCAAA 420
 CAATATTGGA GTGTACGTCA AACAAAACGC ACAAGCGGAA CCGTCTCCGT CAGTGAGCAT 480
 10 TTTAAAAAAT GGGAAAGCTT AGGCATGCCA ATGGGAAAAA TGTATGAAAC AGCATTAACT 540
 GTAGAAGGCT ACCGAAGCAA CGGAAGTGCG AATGTCATGA CGAATCAGCT GATGATTCTGA 600

(2) INFORMATION FOR SEQ ID NO: 27:

15 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 81 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE : genomic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:

ATGAATTTGA AAAGATTGAG GCTGTTGTTT GTGATGTGTA TTGGATTGTG TCTGACACTG 60
 ACGGCTGTGC CGGCTCATGC G 81

(2) INFORMATION FOR SEQ ID NO: 28:

25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 185 base pairs
 (B) TYPE: nucleic acid
 30 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE : genomic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:

35 TCATGTAACT CGCCTTGATC TATTTTCAAT GTATCAAAGG ATTTATACAC AAACAAGAGA 60
 CATCCATGCC GGGTTAAAGC AGTATCGTTC CATCTAACAG AGAAGGNCCTG CATGAAAGGA 120
 GGTGATGGGT TTTTCATCTT AGGGATGACA GAACAATACG GATGAAAAAA GGAGAGGGAT 180
 GGAAA 185

(2) INFORMATION FOR SEQ ID NO: 29:

40 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 156 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 45 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE : genomic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:

50 TAAAAGCATA TGA AAAAAGC CAGCAAAAAA TGGCTGGCTT TTTTCTATGA TAATTTTTC 60
 ACTTCCACTC TGCCAGAAAA GAACGTCGCG CCGCCTCCA TATCTGCCAA TCGATCAGGT 120
 GTTAACCCAT TCACTAAATG CTTTTTGCCT TTTTGA 156

EP 0 634 490 A1

(2) INFORMATION FOR SEQ ID NO: 30:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 681 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: genomic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:

ATGAATTTGA	AAAGATTGAG	GCTGTTGTTT	GTGATGTGTA	TTGGATTGT	GCTGACACTG	60
ACGGCTGTGC	CGGCTCATGC	GGAAACGATT	TATGATAATA	GGATAGGGAC	ACACAGCGGA	120
TACGATTTTG	AATTATGGAA	GGATTACGGA	AATACCTCGA	TGACACTCAA	TAACGGCGGG	180
GCAATTAGTG	CAAGCTGGAA	CAATATTGGA	AATGCCTTAT	TTCGAAAAGG	AAAGAAGTTT	240
GATTCACCTA	AAACTCATCA	TCAACTTGGC	AACATCTCCA	TCAACTACAA	CGCAGCCTTT	300
AACCCGGGCG	GGAATTCCTA	TTTATGTGTC	TATGGCTGGA	CACAATCTCC	ATTAGCTGAA	360
TACTACATTG	TTGAGTCATG	GGGCACATAT	CGTCCAACAG	GAACGTATAA	AGGATCATTT	420
TATGCCGATG	GAGGCACATA	TGACATATAT	GAAACGCTCC	GTGTCAATCA	GCCTTCTATC	480
ATTGAGACG	CTACCTTCAA	ACAATATTGG	AGTGACGTC	AAACAAAACG	CACAAGCGGA	540
ACGGTCTCCG	TCAGTGAGCA	TTTTAAAAAA	TGGGAAAGCT	TAGGCATGCC	AATGGGAAAA	600
ATGTATGAAA	CAGCATTAAC	TGTAGAAGGC	TACCGAAGCA	ACGGAAGTGC	GAATGTCATG	660
ACGAATCAGC	TGATGATTCT	A				681

(2) INFORMATION FOR SEQ ID NO: 31:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 227 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(v) FRAGMENT TYPE: internal fragment

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Bacillus pumilus
(B) STRAIN: PRL B12

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31:

Met	Asn	Leu	Lys	Arg	Leu	Arg	Leu	Leu	Phe	Val	Met	Cys	Ile	Gly	Phe
	-25				-20						-15				
Val	Leu	Thr	Leu	Thr	Ala	Val	Pro	Ala	His	Ala	Glu	Thr	Ile	Tyr	Asp
	-10				-5						1				5
Asn	Arg	Ile	Gly	Thr	His	Ser	Gly	Tyr	Asp	Phe	Glu	Leu	Trp	Lys	Asp
			10					15						20	
Tyr	Gly	Asn	Thr	Ser	Met	Thr	Leu	Asn	Asn	Gly	Gly	Ala	Phe	Ser	Ala
		25						30					35		
Ser	Trp	Asn	Asn	Ile	Gly	Asn	Ala	Leu	Phe	Arg	Lys	Gly	Lys	Lys	Phe
		40				45					50				
Asp	Ser	Thr	Lys	Thr	His	His	Gln	Leu	Gly	Asn	Ile	Ser	Ile	Asn	Tyr
	55					60					65				

EP 0 634 490 A1

Asn Ala Ala Phe Asn Pro Gly Gly Asn Ser Tyr Leu Cys Val Tyr Gly
70 75 80 85
5 Trp Thr Gln Ser Pro Leu Ala Glu Tyr Tyr Ile Val Glu Ser Trp Gly
90 95 100
Thr Tyr Arg Pro Thr Gly Thr Tyr Lys Gly Ser Phe Tyr Ala Asp Gly
105 110 115
10 Gly Thr Tyr Asp Ile Tyr Glu Thr Leu Arg Val Asn Gln Pro Ser Ile
120 125 130
Ile Gly Asp Ala Thr Phe Lys Gln Tyr Trp Ser Val Arg Gln Thr Lys
135 140 145
15 Arg Thr Ser Gly Thr Val Ser Val Ser Glu His Phe Lys Lys Trp Glu
150 155 160 165
Ser Leu Gly Met Pro Met Gly Lys Met Tyr Glu Thr Ala Leu Thr Val
170 175 180
20 Glu Gly Tyr Arg Ser Asn Gly Ser Ala Asn Val Met Thr Asn Gln Leu
185 190 195
Met Ile Arg
200

(2) INFORMATION FOR SEQ ID NO: 32:

- 25 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 681 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
30 (ii) MOLECULE TYPE: genomic DNA
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Bacillus pumilus
(B) STRAIN: PRL B12
35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32:

ATG AAT TTG AAA AGA TTG AGG CTG TTG TTT GTG ATG TGT ATT GGA TTT 48
Met Asn Leu Lys Arg Leu Arg Leu Leu Phe Val Met Cys Ile Gly Phe
-25 -20 -15
40 GTG CTG ACA CTG ACG GCT GTG CCG GCT CAT GCG GAA ACG ATT TAT GAT 96
Val Leu Thr Leu Thr Ala Val Pro Ala His Ala Glu Thr Ile Tyr Asp
-10 -5 1 5
AAT AGG ATA GGG ACA CAC AGC GGA TAC GAT TTT GAA TTA TGG AAG GAT 144
Asn Arg Ile Gly Thr His Ser Gly Tyr Asp Phe Glu Leu Trp Lys Asp
45 10 15 20
TAC GGA AAT ACC TCG ATG ACA CTC AAT AAC GGC GGG GCA TTT AGT GCA 192
Tyr Gly Asn Thr Ser Met Thr Leu Asn Asn Gly Gly Ala Phe Ser Ala
25 30 35
50 AGC TGG AAC AAT ATT GGA AAT GCC TTA TTT CGA AAA GGA AAG AAG TTT 240
Ser Trp Asn Asn Ile Gly Asn Ala Leu Phe Arg Lys Gly Lys Lys Phe
40 45 50

55

EP 0 634 490 A1

	GAT TCC ACT AAA ACT CAT CAT CAA CTT GGC AAC ATC TCC ATC AAC TAC	288
	Asp Ser Thr Lys Thr His His Gln Leu Gly Asn Ile Ser Ile Asn Tyr	
	55 60 65	
5	AAC GCA GCC TTT AAC CCG GGC GGG AAT TCC TAT TTA TGT GTC TAT GGC	336
	Asn Ala Ala Phe Asn Pro Gly Gly Asn Ser Tyr Leu Cys Val Tyr Gly	
	70 75 80 85	
	TGG ACA CAA TCT CCA TTA GCT GAA TAC TAC ATT GTT GAG TCA TGG GGC	384
	Trp Thr Gln Ser Pro Leu Ala Glu Tyr Ile Val Glu Ser Trp Gly	
10	90 95 100	
	ACA TAT CGT CCA ACA GGA ACG TAT AAA GGA TCA TTT TAT GCC GAT GGA	432
	Thr Tyr Arg Pro Thr Gly Thr Tyr Lys Gly Ser Phe Tyr Ala Asp Gly	
	105 110 115	
	GGC ACA TAT GAC ATA TAT GAA ACG CTC CGT GTC AAT CAG CCT TCT ATC	480
15	Gly Thr Tyr Asp Ile Tyr Glu Thr Leu Arg Val Asn Gln Pro Ser Ile	
	120 125 130	
	ATT GGA GAC GCT ACC TTC AAA CAA TAT TGG AGT GTA CGT CAA ACA AAA	528
	Ile Gly Asp Ala Thr Phe Lys Gln Tyr Trp Ser Val Arg Gln Thr Lys	
	135 140 145	
20	CGC ACA AGC GGA ACG GTC TCC GTC AGT GAG CAT TTT AAA AAA TGG GAA	576
	Arg Thr Ser Gly Thr Val Ser Val Ser Glu His Phe Lys Lys Trp Glu	
	150 155 160 165	
	AGC TTA GGC ATG CCA ATG GGA AAA ATG TAT GAA ACA GCA TTA ACT GTA	624
25	Ser Leu Gly Met Pro Met Gly Lys Met Tyr Glu Thr Ala Leu Thr Val	
	170 175 180	
	GAA GGC TAC CGA AGC AAC GGA AGT GCG AAT GTC ATG ACG AAT CAG CTG	672
	Glu Gly Tyr Arg Ser Asn Gly Ser Ala Asn Val Met Thr Asn Gln Leu	
	185 190 195	
30	ATG ATT CGA	681
	Met Ile Arg	
	200	

(2) INFORMATION FOR SEQ ID NO: 33:

35	(i) SEQUENCE CHARACTERISTICS:
	(A) LENGTH: 81 base pairs
	(B) TYPE: nucleic acid
	(C) STRANDEDNESS: single
	(D) TOPOLOGY: linear
40	(ii) MOLECULE TYPE: genomic DNA
	(vi) ORIGINAL SOURCE:
	(A) ORGANISM: Bacillus pumilus
	(B) STRAIN: PRL B12

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33:

45	ATG AAT TTG AAA AGA TTG AGG CTG TTG TTT GTG ATG TGT ATT GGA TTT	48
	Met Asn Leu Lys Arg Leu Arg Leu Leu Phe Val Met Cys Ile Gly Phe	
	-25 -20 -15	
50	GTG CTG ACA CTG ACG GCT GTG CCG GCT CAT GCG	91
	Val Leu Thr Leu Thr Ala Val Pro Ala His Ala	
	-10 -5	

55

EP 0 634 490 A1

(2) INFORMATION FOR SEQ ID NO: 34:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 600 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: genomic DNA

(vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Bacillus pumilus*
 (B) STRAIN: PRL B12

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34:

15	GAA ACG ATT TAT GAT AAT AGG ATA GGG ACA CAC AGC GGA TAC GAT TTT	48
	Glu Thr Ile Tyr Asp Asn Arg Ile Gly Thr His Ser Gly Tyr Asp Phe	
	1 5 10 15	
20	GAA TTA TGG AAG GAT TAC GGA AAT ACC TCG ATG ACA CTC AAT AAC GGC	96
	Glu Leu Trp Lys Asp Tyr Gly Asn Thr Ser Met Thr Leu Asn Asn Gly	
	20 25 30	
25	GGG GCA TTT AGT GCA AGC TGG AAC AAT ATT GGA AAT GCC TTA TTT CGA	144
	Gly Ala Phe Ser Ala Ser Trp Asn Asn Ile Gly Asn Ala Leu Phe Arg	
	35 40 45	
30	AAA GGA AAG AAG TTT GAT TCC ACT AAA ACT CAT CAT CAA CTT GGC AAC	192
	Lys Gly Lys Lys Phe Asp Ser Thr Lys Thr His His Gln Leu Gly Asn	
	50 55 60	
35	ATC TCC ATC AAC TAC AAC GCA GCC TTT AAC CCG GGC GGC AAT TCC TAT	240
	Ile Ser Ile Asn Tyr Trp Ala Ala Phe Asn Pro Gly Gly Asn Ser Tyr	
	65 70 75 80	
40	TTA TGT GTC TAT GGC TGG ACA CAA TCT CCA TTA GCT GAA TAC TAC ATT	288
	Leu Cys Val Tyr Gly Trp Thr Gln Ser Pro Leu Ala Glu Tyr Tyr Ile	
	85 90 95	
45	GTT GAG TCA TGG GGC ACA TAT CGT CCA ACA GGA ACG TAT AAA GGA TCA	336
	Val Glu Ser Trp Gly Thr Tyr Arg Pro Thr Gly Thr Tyr Lys Gly Ser	
	100 105 110	
50	TTT TAT GCC GAT GGA GGC ACA TAT GAC ATA TAT GAA ACG CTC CGT GTC	384
	Phe Tyr Ala Asp Gly Gly Thr Tyr Asp Ile Tyr Glu Thr Leu Arg Val	
	115 120 125	
55	AAT CAG CCT TCT ATC ATT GGA GAC GCT ACC TTC AAA CAA TAT TGG AGT	432
	Asn Gln Pro Ser Ile Ile Gly Asp Ala Thr Phe Lys Gln Tyr Trp Ser	
	130 135 140	
60	GTA CGT CAA ACA AAA CGC ACA AGC GGA ACG GTC TCC GTC AGT GAG CAT	480
	Val Arg Gln Thr Lys Arg Thr Ser Gly Thr Val Ser Val Ser Glu His	
	145 150 155 160	
65	TTT AAA AAA TGG GAA AGC TTA GGC ATG CCA ATG GGA AAA ATG TAT GAA	528
	Phe Lys Lys Trp Glu Ser Leu Gly Met Pro Met Gly Lys Met Tyr Glu	
	165 170 175	

EP 0 634 490 A1

ACA GCA TTA ACT GTA GAA GGC TAC CGA AGC AAC GGA AGT GCG AAT GTC 576
 Thr Ala Leu Thr Val Glu Gly Tyr Arg Ser Asn Gly Ser Ala Asn Val
 180 185 190

5 ATG ACG AAT CAG CTG ATG ATT CGA 600
 Met Thr Asn Gln Leu Met Ile Arg
 195 200

(2) INFORMATION FOR SEQ ID NO: 35:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1022 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: genomic DNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35:

TCATGTAACG CGCCTTGATC TATTTTCATTT GTATCAAAGG ATTTATACAC AAACAAGAGA 60
 CATCCATGCC GGGTTAAAGC AGTATCGTTC CATCTAACAG AGAAGGNCTG CATGAAAGGA 120
 GGTGATGGGT TTTTCATCTT AGGGATGACA GAACAATACG GATGAAAAAA GGAGAGGGAT 180
 GGAAAATGAA TTTGAAAAGA TTGAGGCTGT TGTGTGTGAT GTGTATTGGA TTTGTGCTGA 240
 CACTGACGGC TGTGCCGGCT CATGCGGAAA CGATTTATGA TAATAGGATA GGGACACACA 300
 GCGGATACGA TTTTGAATTA TGGAAGGATT ACGGAAATAC CTCGATGACA CTCAATAACG 360
 GCGGGGCATT TAGTGCAAGC TGGAACAATA TTGGAATGCT CTTATTTTGA AAAGGAAAGA 420
 AGTTTGATTC CACTAAACT CATCATCAAC TTGGCAACAT CTCCATCAAC TACAACGCAG 480
 CCTTTAACCC GGGCGGGAAT TCCTATTTAT GTGTCTATGG CTGGACACAA TCTCCATTAG 540
 CTGAATACTA CATTGTTGAG TCATGGGGCA CATATCGTCC AACAGGAACG TATAAAGGAT 600
 CATTTTATGC CGATGGAGGC ACATATGACA TATATGAAAC GCTCCGTGTC AATCAGCCTT 660
 CTATCATTTG AGACGCTACC TTCAAACAAT ATTGGAGTGT ACGTCAAACA AAACGCACAA 720
 GCGGAACGGT CTCCGTCAGT GAGCATTTTA AAAAATGGGA AAGCTTAGGC ATGCCAATGG 780
 GAAAAATGTA TGAAACAGCA TTAACGTGAG AAGGCTACCG AAGCAACGGA AGTGCGAATG 840
 TCATGACGAA TCAGCTGATG ATTCGATAAA AGCATATGAA AAAAGCCAGC AAAAAATGGC 900
 TGGCTTTTTT CTATGATAAT TTTTCAACTT CCACTCTGCC AGAAAAGAAC GTCGCGCCGC 960
 CTCCCATATC TGCCAATCGA TCAGGTGTTA ACCCATTCAC TAAATGCTTT TTGCCTTTTT 1020
 GA 1022

Claims

1. A purified xylanase derived from Bacillus pumilus PRL B12 and mutants and variants thereof.
2. A purified xylanase essentially consisting of the amino acid sequence of amino acids 1-200 of figures 1a and 1b (SEQ ID NO:24).
3. The xylanase of claim 2, obtainable from a xylanase-producing strain of Bacillus pumilus.
4. A xylanase heterologously-produced by a microorganism of the genus Bacillus having a naturally-occurring alkaline protease gene.
5. The xylanase of claim 4, wherein the microorganism has the alkaline protease gene deleted therefrom.
6. A xylanase produced by a transformed strain of B. licheniformis.
7. A process for producing a xylanase in a Bacillus species including transforming a suitable strain of a Bacillus with a nucleotide sequence (SEQ ID NO: 26) coding for at least the mature portion of the xylanase (SEQ ID NO:24), so that a Bacillus having a complete xylanase gene expression unit is formed, culturing the Bacillus under suitable conditions for the expression of xylanase and recovering the xylanase from the culture.

8. The process of claim 7, wherein the Bacillus is Bacillus licheniformis.
9. The process of claim 7, wherein the nucleotide sequence is derived from Bacillus pumilus PRL B12.
- 5 10. A DNA molecule comprised of a nucleotide sequence coding for the mature xylanase of B. pumilus PRL B12 (SEQ ID NO:26).
11. The DNA molecule of claim 10, further including the nucleotide sequence coding for the presequence xylanase of B. pumilus PRL B12 (SEQ ID NO:27).
- 10 12. The DNA molecule of claim 10, further including the upstream nucleotide sequences of the xylanase gene of B. pumilus PRL B12 (SEQ ID NO:28)
13. A DNA molecule comprised of an isolated xylanase gene of Bacillus pumilus PRL B12 (SEQ ID NO: 1).
- 15 14. An expression vector including the DNA molecule of claim 13.
15. Expression vector pUB-BPX12.
- 20 16. Expression vector pUBDEBRA1.
17. Expression vector pLI1.
18. Expression vector pKAC1.
- 25 19. Expression vector pL7SBT.
20. Expression vector pL7TAKA.
- 30 21. A method for the preparation of a strain of Bacillus licheniformis comprised of performing at least one chromosomal deletion of the alkaline protease gene of the B. licheniformis, whereby a Bacillus licheniformis having at least one chromosomal deletion is provided.
22. Bacillus licheniformis SE2 and mutants and variants thereof.
- 35 23. Bacillus licheniformis SE2 delap1 and mutants and variants thereof.
24. Bacillus licheniformis SE2 delap3 and mutants and variants thereof.
- 40 25. Bacillus licheniformis SE2 delap6 and mutants and variants thereof.
26. A Bacillus licheniformis transformed with the DNA molecule of claim 10 (SEQ NO ID:26).
27. The Bacillus licheniformis SE2 delap1 of claim 23, transformed with the DNA molecule of claim 10 (SEQ ID NO:26).
- 45 28. Bacillus licheniformis SE2 delap1 (pUB-BPX12) and mutants and variants thereof.
29. Xylanase produced by the transformed strain of B. licheniformis of claim 28.
- 50 30. A method for the treatment of lignocellulosic pulp comprising treating the wood pulp with a xylanase derived from Bacillus pumilus PRL B12.
31. The method of claim 30, wherein the method is comprised of pretreating the lignocellulosic pulp.
- 55 32. A method of treating lignocellulosic kraft pulp comprising treating the lignocellulosic pulp with a xylanase derived from Bacillus pumilus PRL B12.

TCATGTAAC	CGCCTTGATC	TATTTCA	TTT	GTATCAAAGG	ATTTATACAC	50
AAACAAGAGA	CATCCATGCC	GGGTAAAGC	AGTATCGTTC	CATCTAACAG		100
AGAAGGNCTG	CATGAAAGGA	GGTGATGGGT	TTTTCATCTT	AGGGATGACA		150
GAACAATACG	GATGAAAAAA	GGAGAGGGAT	GGAAA	ATG		188
			Met			
AAT TTG AAA	AGA TTG AGG	CTG TTG TTT	GTG ATG TGT	ATT		227
Asn Leu Lys	Arg Leu Arg	Leu Leu Phe	Val Met Cys	Ile		
-25		-20		-15		
GGA TTT GTG	CTG ACA CTG	ACG GCT GTG	CCG GCT CAT	GCG		266
Gly Phe Val	Leu Thr Leu	Thr Ala Val	Pro Ala His	Ala		
	-10		-5			
GAA ACG ATT	TAT GAT AAT	AGG ATA GGG	ACA CAC AGC	GGA		305
Glu Thr Ile	Tyr Asp Asn	Arg Ile Gly	Thr His Ser	Gly		
1		5		10		
TAC GAT TTT	GAA TTA TGG	AAG GAT TAC	GGA AAT ACC	TCG		344
Tyr Asp Phe	Glu Leu Trp	Lys Asp Tyr	Gly Asn Thr	Ser		
15		20		25		
ATG ACA CTC	AAT AAC GGC	GGG GCA TTT	AGT GCA AGC	TGG		383
Met Thr Leu	Asn Asn Gly	Gly Ala Phe	Ser Ala Ser	Trp		
	30		35			
AAC AAT ATT	GGA AAT GCC	TTA TTT CGA	AAA GGA AAG	AAG		422
Asn Asn Ile	Gly Asn Ala	Leu Phe Arg	Lys Gly Lys	Lys		
40		45		50		
TTT GAT TCC	ACT AAA ACT	CAT CAT CAA	CTT GGC AAC	ATC		461
Phe Asp Ser	Thr Lys Thr	His His Gln	Leu Gly Asn	Ile		
	55		60	65		
TCC ATC AAC	TAC AAC GCA	GCC TTT AAC	CCG GGC GGG	AAT		500
Ser Ile Asn	Tyr Asn Ala	Ala Phe Asn	Pro Gly Gly	Asn		
	70		75			
TCC TAT TTA	TGT GTC TAT	GGC TGG ACA	CAA TCT CCA	TTA		539
Ser Tyr Leu	Cys Val Tyr	Gly Trp Thr	Gln Ser Pro	Leu		
80		85		90		

FIG. 1a

EP 0 634 490 A1

GCT GAA TAC TAC ATT GTT GAG TCA TGG GGC ACA TAT CGT Ala Glu Tyr Tyr Ile Val Glu Ser Trp Gly Thr Tyr Arg 95 100	578
CCA ACA GGA ACG TAT AAA GGA TCA TTT TAT GCC GAT GGA Pro Thr Gly Thr Tyr Lys Gly Ser Phe Tyr Ala Asp Gly 105 110 115	617
GGC ACA TAT GAC ATA TAT GAA ACG CTC CGT GTC AAT CAG Gly Thr Tyr Asp Ile Tyr Glu Thr Leu Arg Val Asn Gln 120 125 130	656
CCT TCT ATC ATT GGA GAC GCT ACC TTC AAA CAA TAT TGG Pro Ser Ile Ile Gly Asp Ala Thr Phe Lys Gln Tyr Trp 135 140	695
AGT GTA CGT CAA ACA AAA CGC ACA AGC GGA ACG GTC TCC Ser Val Arg Gln Thr Lys Arg Thr Ser Gly Thr Val Ser 145 150 155	734
GTC AGT GAG CAT TTT AAA AAA TGG GAA AGC TTA GGC ATG Val Ser Glu His Phe Lys Lys Trp Glu Ser Leu Gly Met 160 165	773
CCA ATG GGA AAA ATG TAT GAA ACA GCA TTA ACT GTA GAA Pro Met Gly Lys Met Tyr Glu Thr Ala Leu Thr Val Glu 170 175 180	812
GGC TAC CGA AGC AAC GGA AGT GCG AAT GTC ATG ACG AAT Gly Tyr Arg Ser Asn Gly Ser Ala Asn Val Met Thr Asn 185 190 195	851
CAG CTG ATG ATT CGA TAA AAGCATATGA AAAAAAGCCAG CAAAAAATGG Gln Leu Met Ile Arg 200	899
CTGGCTTTTT TCTATGATAA TTTTTCAACT TCCACTCTGC CAGAAAAGAA CGTCGCGCCG CCTCCCATAT CTGCCAATCG ATCAGGTGTT AACCCATTCA CTAAATGCTT TTTGCCTTTT TGA	949 999 1022

FIG. 1b




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10




FIG. 11




FIG. 12




FIG. 13



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 94 20 2002

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
D,X	WO-A-92 03540 (NOVO NORDISK) 5 March 1992 * the whole document * ---	1,4-6, 29-32	C12N15/56 C12N9/24 C12N1/21 C12N15/57 C12N15/75
X	FEBS LETTERS, vol.171, no.2, June 1984, AMSTERDAM NL pages 197 - 201 FUKUSAKI E. ET AL. 'The complete nucleotide sequence of xylanase gene (xynA) of Bacillus pumilus' * figure 2 * ---	1,4-6, 29-32	/(C12N1/21, C12R1:10, C12R1:125, C12R1:19), (C12N9/24, C12R1:07)
X	BIOCHEM. J., vol.288, November 1992 pages 117 - 121 KO E.P. ET AL. 'Site-directed mutagenesis at aspartate and glutamate residues of xylanase from Bacillus pumilus' * figures 3,4 * ---	1,4-6, 29-32	
X	MOLECULAR AND GENERAL GENETICS, vol.192, 1983, BERLIN DE pages 335 - 341 PANBANGRED W. ET AL. 'Molecular cloning of the genes for xylan degradation of Bacillus pumilus and their expression in Escherichia coli' * the whole document * ---	1-7	TECHNICAL FIELDS SEARCHED (Int.Cl.6) C12N
X	VISSER J. ET AL. (EDS.) 'Xylans and Xylanases' 1992, ELSEVIER SCIENCE PUBLISHERS B. V., AMSTERDAM-LONDON-N. Y.-TOKYO Nissen A. M. et al.: Xylanases for the pulp and paper industry * page 325 - page 337 * --- -/--	1-6, 29-32	
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 27 October 1994	Examiner Espen, J
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons * : member of the same patent family, corresponding document			



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 94 20 2002

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. CL. 6)
X	JP-A-60 075 286 (HIROSUKE OKADA) 28 September 1983 * see abstract * -----	1-6	
			TECHNICAL FIELDS SEARCHED (Int. CL. 6)
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 27 October 1994	Examiner Espen, J
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons Δ : member of the same patent family, corresponding document			